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Abstract 
 
Breast cancer survivors (BCS) account for the largest group of cancer survivors living in 
the United States and they often experience lingering physical symptoms that may affect quality 
of life, with fatigue and pain the most commonly reported. This genetic research study was 
conducted within a parent R01 study, with the purpose of exploring associations between genetic 
variants and fatigue and pain symptoms and the Mindfulness-Based Stress Reduction for Breast 
Cancer (MBSR(BC)) program. The aims of this study were to: 1) identify specific genotypes 
involved in fatigue and pain symptoms, and 2) explore whether single nucleotide polymorphism 
(SNP) rs1800795 in gene IL6, SNP rs16944 in gene IL1B, and SNP rs4680 in gene COMT, 
moderate the effects of the MBSR(BC) intervention on fatigue and/or pain symptoms. 
As part of a larger R01 trial, one-hundred-fifty-eight participants were randomized to 
either a six-week MBSR(BC) intervention or Usual Care (UC). Data were collected at baseline, 
six-week, and 12-weeks on subjective measures of pain, fatigue, along with demographic and 
clinical history information. In addition, DNA was collected for genotyping among the 158 
participants using the PCR analysis method. For Aim 1, one-way linear trend analysis of 
variances (ANOVAs) were implemented to explore associations between the SNPs in genes with 
subjective symptom measures of pain and fatigue. For Aim 2, comparison of mean scores along 
with linear mixed model (LMM) analyses were used to explore if the patient’s SNPs moderated 
the effects of the MBSR(BC) intervention on fatigue and pain symptoms. 
Results found the mean age of the total sample was 58.4 years and 89% were White, non-
Hispanic. Although participants were randomized 1:1 to either the MBSR(BC) or UC groups, chi 
square analyses found that there was a significant difference for time since treatment, with the 
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UC group being closer to treatment end (< 1 year) than the MBSR(BC) group (p < .05). No other 
statistically significant differences between groups for baseline demographic or clinical 
characteristics were found. For Aim 1, one-way linear trend ANOVAs among fatigue and pain 
scores and the three SNPs (COMT rs4680, IL1B rs16944, IL6 1800795) included as part of this 
study, fatigue and/or pain, resulted in no statistically significant associations (p > .05). Linear 
Mixed Model (LMM) analyses, implemented to assess the between-group interactions between 
pain and/or fatigue symptom, time, and SNP, resulted in no statistically significant findings for 
SNP rs4680 in COMT and SNP rs16944 in IL1B, however significant findings were found for the 
interaction between assignment (MBSR(BC) versus UC) and genotype for SNP rs1800795 in 
IL6. Second, a comparison of means suggests that participants in the MBSR(BC) group who had 
CG genotype for SNP rs1800795 in IL6 benefited more from the intervention than those with CC 
or GG genotypes for fatigue severity, fatigue interference, pain severity, and pain interference, 
with small to large effect sizes ranging from d = 0.38 to d = 0.72. Although this genetic study 
was exploratory in nature, the results suggests that the effects of the MBSR(BC) program may be 
moderated by SNPs in genes that are involved in cytokine production, which means that BCS 
with specific genotypes experience a greater improvement in symptoms than those with other 
genotypes. The results of this study also suggest that further research is needed, with larger 
sample sizes, to assess the genetic moderation of symptoms experienced by BCS. 
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Chapter One 
 
Introduction  
 
Background 
 Breast cancer in the United States. Breast cancer is the most prevalent form of cancer 
in women and in 2018 in the United States, there were over 3.1 million women with a history of 
breast cancer, including patients and survivors (U.S. Breast Cancer Statistics, 2018).  Breast 
cancer is increasing in prevalence and as new discoveries of improvements for the detection and 
treatment of cancers rise, the number of cancer survivors continues to rise also (Siegel, Miller, & 
Jemal, 2018).  Breast cancer is expected to account for 30% of all cancer cases in 2018 
(American Cancer Society, 2017) and approximately one in eight women in the United States 
will develop invasive breast cancer at some point in life (U.S. Breast Cancer Statistics, 2018).  
Breast cancer survivors comprise the largest group of cancer survivors living in the United 
States, with an estimated five-year breast cancer survival rate of 91% in 2017 (American Cancer 
Society, 2017). Unfortunately, many BCS suffer from a multitude of adverse symptoms after 
treatment that can affect quality of life. 
 Physical symptoms and quality of life in women with breast cancer.  Despite 
successful treatment, BCS often experience lingering physical symptoms that may affect their 
quality of life.  Survivors of breast cancer report pain, fatigue, neuropathies such as weakness, 
tingling, and numbness, sexual dysfunction, bone and joint problems, lymphedema, skin 
changes, memory loss, and decreased immune function after cancer treatment ends. Fatigue and 
pain are reported to be the most commonly experienced physical symptoms and are often co-
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occurring (Reich et al., 2017a; Miaskowski et al., 2007), and have been shown to be strongly 
associated with satisfaction with quality of life (Gavric-Kostic, 2016; Hamer et al., 2016).  
Fatigue in BCS.  Fatigue is a very common symptom that plagues BCS and the National 
Cancer Institute (2015) has included cancer-related fatigue as one of the “first tier high-priority 
areas for research.” In a study by Lengacher et al. (2012), 85% of BCS suffered from fatigue, 
making it one of the top two most common adverse effects of cancer treatment. Women with 
breast cancer report fatigue to be one of the most distressing symptoms related to cancer 
treatment, which has been shown to be strongly associated with satisfaction with quality of life 
(Bower, 2014; Gupta, Lis, & Grutsch, 2007). Cancer patients can experience fatigue long after 
treatment ends, and chronic fatigue has been defined as fatigue lasting for a period of at least six 
consecutive months (Wessely, Hotopf, & Sharpe, 1998). Approximately one-third of extensively 
treated disease-free BCS experience chronic fatigue up to ten years after breast cancer diagnosis 
(Bower, 2014; Bower et al., 2006; Reinertsen et al., 2010; Servaes, Gielissen, Verhagen, & 
Bleijenberg, 2006).  It is unknown how cancer treatments cause fatigue, but common cancer 
treatments contributing to cancer-related fatigue include chemotherapy, radiation therapy, 
biologic therapy, and surgery (National Cancer Institute, 2014).  
Pain in BCS.  Pain is highly prevalent among BCS. Breast cancer survivors comprise the 
greatest percentage of cancer survivors reporting problems related to pain or discomfort (Jefford 
et al., 2017). In a study by Lengacher et al. (2012), 60% of BCS suffered from pain, and a study 
on a specific category of pain such as persistent pain found that approximately 25-60% of 
women experience persistent pain after mastectomy (Gartner et al., 2009), making pain one of 
the top two most common adverse effects of cancer treatment. Pain is also highly deleterious, 
with an approximate rate of 5-10% of cancer survivors experiencing chronic pain so severe that 
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it interferes with functioning (Glare et al., 2014). Pain may plague BCS for years after treatment 
ends.  
The physical symptom experience and genetics.  Cancer survivors have their own 
unique symptom experiences, with some suffering more or less from post-treatment symptoms 
(Avis, Levine, Marshall, & Ip, 2017). The variance in frequency and intensity of symptoms 
experienced by BCS may be partly explained by individual genetic factors (Doong et al., 2015; 
Shi et al., 2015).  Genetic factors predicting patient outcomes from adverse symptoms such as 
pain and fatigue may lead to better quality of life for BCS utilizing personalized therapies based 
on individual needs. Genetics and genomics in cancer screening, diagnosis, treatment, and 
particularly for symptom management after behavioral interventions, are increasingly in the 
forefront of cutting edge research.  Aside from screening purposes, focus on genetics may prove 
to be an important piece in predicting symptom outcomes experienced by BCS.  The assessment 
of common genetic variations can be beneficial for outcomes in patients with cancer, and with 
the revolutionary advances in molecular technology, associations between genetic variations and 
symptoms experienced by cancer patients are of great importance.  There is a need to 
individualize treatment for fatigue and pain in women with breast cancer, particularly BCS, and 
genetic studies can contribute to the field of precision medicine, to tailor complementary and 
alternative medicine therapies to best suit patients’ needs (Grady & Gough, 2015).  
Interventions to improve fatigue and pain in BCS.  According to the Department of 
Health, Macmillan Cancer Support, and NHS Improvement’s National Cancer Survivorship 
Initiative Vision (2010), as the growth of cancer survivors increases, future survivorship care 
should be tailored to meet the needs of individual cancer survivors and support for self-
management care needs to be expanded. The American Cancer Society and American Society of 
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Clinical Oncology developed and released a Breast Cancer Survivorship Care Guideline in 2015, 
which details recommendations for managing side effects.  Current survivorship care for post-
treatment symptoms in BCS include pharmacological and non-pharmacological therapies. 
However, as many pharmacological treatments cause other unwanted side effects, evidence 
supports the use of non-pharmacological treatments, which appear to be a safer alternative 
(Blaes, Kreitzer, Torkelson, & Haddad, 2011). Multiple non-pharmacological interventions have 
been used for the management of post-treatment side effects after breast cancer. Non-
pharmacological strategies include psychological and behavioral interventions, exercise 
interventions, and complementary and alternative medicine techniques (Palesh et al., 2017).  
Currently, non-pharmacological level one recommendations for treatment of fatigue in 
cancer survivors are exercise and cognitive behavioral therapy (Runowicz et al., 2016). 
Unfortunately, an estimated up to 70% of BCS do not discuss exercise with their oncology 
providers or exercise according to public health guidelines set forth by the American College of 
Sports Medicine (Palesh et al., 2017). In addition, age, physical limitations, and other 
comorbidities may pose a problem for cancer survivors when participating in an exercise 
program. Fortunately, other interventions are promising and have been found to improve the 
quality of life in BCS by reducing adverse side effects that sometimes remain after cancer 
treatment ends, including stress-reducing techniques (Carlson et al., 2013) such as Mindfulness-
Based Stress Reduction (Lengacher et al., 2016) and acupressure (Rosenberg, 2016; Yeh et al., 
2016), acupuncture (Tao et al., 2016) and massage (Kinkead et al., 2018). 
Non-pharmacological level one recommendations for the management of pain in BCS 
include physical activity and acupuncture (Runowicz et al., 2016). Acupuncture has been found 
to be an effective treatment for pain in cancer patients (Tao et al., 2016), as well as exercise 
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interventions (Galiano-Castillo et al., 2016). Unfortunately, many BCS who were treated with 
aromatase inhibitors experience musculoskeletal symptoms (aromatase inhibitor-induced 
arthralgia) resulting from the medication, and although exercise is recommended to treat this side 
effect, BCS experiencing aromatase inhibitor-induced arthralgia report exercising less than those 
who were not treated with aromatase inhibitors, possibly as a result of impaired lower extremity 
function and joint pain (Brown et al., 2014).  
Mindfulness-based stress reduction. Mindfulness-Based Stress Reduction for Breast 
Cancer (MBSR(BC)) is a stress-reducing technique that has been proven effective in improving 
symptoms experienced by women with breast cancer after treatment (Lengacher et al., 2012). 
The MBSR(BC) program is a six-week complementary alternative medicine program adapted 
and tested by Lengacher et al. (2009) from Dr. Jon Kabat-Zinn’s original eight-week program 
aimed at reducing stress through self-regulation of symptoms to improve the quality of life in 
BCS (Lengacher et al., 2009). Positive effects have been found through its utilization towards 
treating anxiety, cognitive impairment, depression, fatigue, fear of recurrence, and sleep 
disturbances in BCS (Lengacher et al., 2009, 2015, 2016, 2017). 
Precision medicine in cancer survivorship. Precision medicine is a medical model that 
suggests that healthcare be personalized to each individual patient, including its selection of 
treatments and services, and takes into account each individual’s genetic makeup, or, 
“genotype.” The basis for this medical model is that there is no “one size fits all” solution to the 
problem; Every patient is unique in the way that they respond to certain therapies. Individual 
biological responses may vary and often are due in part to the genes within their DNA, which 
encode amino acid sequences, which shape the way bodies function. A treatment that works for 
one patient may not be as effective for another (Ziegelstein, 2017). Although the concept of 
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precision medicine has existed for some time, in 2015 during his State of the Union address, 
United States President Barack Obama declared the launch of the Precision Medicine Initiative, 
investing $215 million in 2016 towards biomedical advances that will supply healthcare 
providers with new knowledge and tools to personalize treatments for the best outcomes. 
Statement of the Problem 
The American Cancer Society and the American Society of Clinical Oncology (2016) 
developed breast cancer survivorship care guidelines for assessing and managing physical, 
psychological, and social long-term effects that recommended that interventions be tailored to 
the needs and abilities of the individual breast cancer survivor (Runowicz et al., 2016). 
Statement of the Purpose 
 The purpose of this study was to explore potential genetic variations that may or may not 
moderate pain and fatigue symptoms among women with BC who participated in a MBSR(BC) 
program.  This study was conducted in part as a secondary data analysis within the RO1 MBSR 
Symptom Cluster Trial for Breast Cancer Survivors/1R01CA131080. 
Research Aims and Hypotheses 
The overall objective of this research study was to explore whether individual genetic 
variants moderate improvement of fatigue and pain symptoms resulting from the MBSR(BC) 
program. It was hypothesized that specific single nucleotide polymorphisms (SNPs) of genes are 
associated with fatigue and pain in BCS, and may moderate improvement from MBSR(BC).  
The primary study aims of this research are as follows:  
Aim 1: To identify the specific genotypes related to symptoms of fatigue and pain among BCS. 
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 Hypothesis 1: It is hypothesized that specific genotypes in SNPs COMT rs4680, IL1B 
rs16944, and IL6 rs1800795 are associated with higher or lower levels of pain and fatigue among 
BCS. 
Aim 2: To explore whether the single nucleotide polymorphism (SNP) rs1800795 in gene IL6, 
SNP rs16944 in gene IL1B, and SNP rs4680 in gene COMT, moderate the effects of the 
MBSR(BC) intervention on fatigue and/or pain symptoms. 
 Hypothesis 2: It is hypothesized that the SNPs IL6 rs1800795, IL1B rs16944, and COMT 
rs4680, will positively moderate symptoms of fatigue and pain among BCS participating in the 
MBSR(BC) intervention compared to the UC group. 
Definitions of Relevant Terms 
The definitions of relevant terms that were used in this study are as follows: 
1. Gene: The basic unit of heredity, made up of DNA, which act as instructions to make 
proteins and determines characteristics (Genetics Home Reference, 2018a). 
2. Genotype: The two alleles inherited for a particular gene; An individual’s collection of 
genes (National Human Genome Research Institute, 2018). 
3. Fatigue: The subjective phenomenon of a sense of persistent tiredness or exhaustion 
that is commonly distressing, measured by the Fatigue Symptom Inventory (Donovan 
& Jacobsen, 2011). 
4. Fatigue Severity: A subscale of the Fatigue Symptom Inventory that assesses the level 
of fatigue in the past week as well as current fatigue (Radiation Therapy Oncology 
Group, 2010). 
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5. Fatigue Interference: A subscale of the Fatigue Symptom Inventory that assesses the 
degree to which fatigue in the past week hindered on daily activities and mood 
(Radiation Therapy Oncology Group, 2010). 
6. Mindfulness-Based Stress Reduction for Breast Cancer (MBSR(BC)): A 6-week clinical 
program designed to assist BCS in self-managing stress and symptoms through 
meditative activities (Lengacher et al., 2009; Reich et al., 2017a). 
7. Pain: An unpleasant feeling experienced physically or emotionally, often associated 
with previous tissue damage, measured by the Brief Pain Inventory (Cleeland, 2009; 
IASP Task Force on Taxonomy, 2017).   
8. Pain Severity: A subscale of the Brief Pain Inventory that assesses the degree of pain 
intensity (Cleeland, 2009). 
9. Pain Interference: A subscale of the Brief Pain Inventory that assesses the impact of 
pain on functioning in daily activities (Cleeland, 2009). 
10. Single Nucleotide Polymorphism: A variation in a gene that represents a difference in a 
single DNA base (Genetics Home Reference, 2018b). 
11. Usual Care: Participation by the control group in standard treatments after cancer 
treatment ends. Participants were asked not to participate in a mindfulness program 
until the study ended (Lengacher et al., 2009; Reich et al., 2017a). 
Delimitations 
The sample included: 
1. Women at least 21 years of age or older 
2. Diagnosed with early stage breast cancer (Stage 0-III) 
3. Surgically treated (lumpectomy and/or mastectomy) 
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4. Are at least two weeks out from or a maximum of two years out from completion of 
adjuvant radiation and/or chemotherapy 
Exclusion criteria consisted of the following: 
1. Diagnosed with advanced stage breast cancer (Stage IV) 
2. Self-reported a severe current psychiatric diagnosis  
3. Received treatment for recurrent breast cancer 
Limitations  
 This study is the first step in exploring the potential genetic moderation of pain and 
fatigue symptoms in BCS participating in a MBSR(BC) program. Study limitations include: 
1. This study included only Hispanic and non-Hispanic white women; generalizations to 
women of other races and men are limited. 
2. The sample size was small for a genetic study. Sufficient statistical power is critical for 
the detection of genetic association and moderation studies. 
3. This study explores the presence or absence of SNPs and their association with symptoms 
experienced by BCS, however, it does not address gene expression, which leaves an open 
gap between the presence of SNPs and their effects on protein synthesis. 
4. Although genotype was identified for genes involved in inflammatory and anti-
inflammatory pathways, there were no direct measures of systemic levels of circulating 
IL6 and IL1B, which would have provided supplementary information on the latent 
mechanisms for pain and fatigue severity. 
5. There was no assessment of fatigue or pain prior to a breast cancer diagnosis, so it is 
impossible to determine if there were pre-existing symptoms prior to cancer treatment. 
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6. As there was no healthy control group, inferences cannot be made about the relationship 
between these genetic variations and fatigue and pain in the general population or in 
people with other types of cancer (prostate, lung, etc). 
Significance of the Study 
 There is limited empirical knowledge and data regarding the relationships between 
fatigue and pain-associated single nucleotide polymorphisms (SNPs), and mind-body therapies 
such as the MBSR(BC) program. This study will contribute to symptom science and precision 
medicine by exploring these associations and disseminating findings to target optimal therapies 
for BCS based on their genetic profiles, which may help improve quality of life. Although this 
study is exploratory in nature and lacks the larger sample size needed for the precision of genetic 
association research, it is anticipated that this study will warrant future research involving larger 
clinical trials on the genetic moderation of symptoms experienced by BCS as well as the use of 
MBSR(BC) to treat such symptoms. 
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Chapter Two 
Literature Review 
Introduction 
 Chapter two introduces the theoretical framework, the hypothesized research model, and 
a review literature on the study variables in this dissertation. First, a review of empirical research 
will be presented on pain and fatigue symptoms experienced by BCS. This review is followed by 
a review of empirical literature on genetic variants (single nucleotide polymorphisms) associated 
with pain and fatigue. Concluding this review is a review of complementary and alternative 
medicine therapies used to treat pain and fatigue, particularly the Mindfulness-Based Stress 
Reduction for Breast Cancer Program, which is the intervention implemented in this study. 
Theoretical Framework and Hypothesized Research Model 
This research was guided by a hypothesized research model, which was adapted from a 
logic model based upon the Psychosocial Nursing Research Model (Evans (1992). The 
hypothesized research model postulates that: 
• Outcomes resulting from the Mindfulness-Based Stress Reduction for Breast Cancer 
(MBSR(BC)) program are moderated by genetic variations such as single nucleotide 
polymorphisms (SNPs).  
• Changes in physical symptoms (fatigue and pain) resulting from MBSR(BC) are 
expected to improve from baseline to 6 and 12-week assessments to a greater or lesser 
degree based on genetic profile.  
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Figure 1. Hypothesized Research Model 
 
Review of Empirical Literature 
 This review of empirical literature examined the variables within this study. First, a 
review of research on physical symptoms experienced by BCS, with a particular focus on fatigue 
and pain as they are the main symptom outcomes of this study, are presented. Next, genetic 
polymorphisms that have been found to be associated in fatigue and pain symptom pathways are 
reviewed, followed by mind-body interventions such as MBSR(BC), which was used to treat 
fatigue and pain symptoms by this study’s participants in the intervention group.  
 Post-treatment physical symptoms in BCS. Breast cancer survivors commonly suffer 
from treatment-related symptoms that may linger for years after treatment ends, which are often 
distressing (Syrowatka et al., 2017) and decrease quality of life (Gavric-Vukovic-Kostic, 2016; 
Koch et al., 2013). In a systematic review of 243 studies by Zomkowksi et al. (2018) on physical 
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symptoms and their interference with the ability to perform work tasks in BCS, the investigators 
found that the most commonly reported symptoms included pain, fatigue, lymphedema, arm 
and/or breast paresthesia, decreased range of motion and weakness in the upper limbs. Evidence 
shows that fatigue and pain are two of the most commonly experienced symptoms in BCS 
(Doong et al., 2015; Lengacher et al., 2012). Research also suggests that the patients’ symptoms 
vary among individuals, suggesting a need for individualized treatments for symptom 
management (Miaskowski et al., 2015). 
 Pain. The symptom of pain is one of the main subjective variables in this analysis. In this 
section, a review of the definition of pain is presented, followed by its prevalence among BCS. 
The effects of pain on quality of life in BCS and its interference with the ability to complete 
daily activities are also reviewed. Finally, the etiology of pain and its risk factors among BCS are 
examined and presented.  
 Pain is often viewed as the fifth vital sign (Lynch, 2001) and is a complex process that 
varies among patients and may be easily misunderstood as it is often defined subjectively and 
may seem disproportional to physical signs observed by clinicians.  Pain is a subjective 
experience and its definition varies. The International Association for the Study of Pain (2017) is 
a collaboration of scientists, clinicians, health-care providers, and policymakers who are 
dedicated to studying pain and translating research findings into pain relief for patients 
worldwide.  They have defined pain as “an unpleasant sensory and emotional experience 
associated with actual or potential tissue damage, or described in terms of such damage” (Pain, 
International Association for the Study of Pain, 2017). Among breast cancer patients, a study by 
Hickey et al. (2011) involving persistent breast pain after mastectomy with reconstruction 
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described pain as “itching”, “burning”, “tightness”, “ache”, “piercing”, “annoying”, 
“exhausting”, and “miserable”.  
Pain is highly prevalent among BCS. In a cross-sectional study of 410 BCS by Hamood, 
Hamood, Merhasin, and Keinan-Boker (2017) on the prevalence and risk factors associated with 
chronic pain and other symptoms related to breast cancer and its treatment, the investigators 
found that 74% of BCS reported chronic pain, of which 84% reported the pain to be moderate. 
The median since diagnosis was 7.4 years. Pain was assessed using a numeric pain rating scale 
from 0 (no pain) to 10 (worst pain imaginable) and higher ratings were found to be significantly 
associated with decreased quality of life (p < 0.001), which was assessed using the 36-item short-
form health survey (SF-36). Breast cancer survivors were found to have a positive association 
with chronic pain if they received mastectomy vs. breast conserving surgery (p = 0.005), 
radiotherapy vs. non-radio therapy (p = 0.003), regional breast cancer vs. localized at time of 
diagnosis (p < 0.001), younger vs. older age (p = 0.002), and time since diagnosis (p < 0.001). 
The pain that BCS experience may often affect quality of life. A study by Gavric & 
Vukovic-Kostic (2017) involving BCS found that pain negatively influenced quality of life. The 
authors assessed quality of life using a self-report questionnaire (QLQ-C30- The Core Quality of 
Life Questionnaire of The European Organization for Research and Treatment of Cancer, version 
3.0) among 100 women. The questionnaire consisted of five functional scales: Physical 
functioning; Role functioning; Emotional functioning Cognitive and Social functioning; and 
three scales of symptoms: pain, nausea/vomiting, Dyspnea, Insomnia, Appetite loss, 
Constipation and Diarrhea. Although there were statistically significant differences in emotional, 
role, and social functions, one of the most influential was the symptom of pain. In another study, 
Rim et al. (2017) investigated the quality of life of BCS during the first three years after breast 
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cancer treatment including radiotherapy.  Their large sample of 1156 participants were drawn 
from 17 hospitals and the patients were separated into three groups (first, second, and third year 
from the end of radiotherapy).  Participants were asked to complete two self-administered quality 
of life questionnaires: The breast cancer-specific module of the EORTC Quality of Life 
Questionnaire and the 5-dimensional questionnaire by the EuroQol group (EQ-5D). It was found 
through the 3-grade Likert scale of the EQ-5D that the worst grades for problems related to 
health status (2 = some/moderate problem; 3 = extreme problem) were in the pain/discomfort 
category among the total participants (p < 0.001). Results also showed that pain/discomfort was 
significantly associated with less satisfaction with quality of life but improved with each time 
period (i.e. year one to year two, year two to year three) (p < 0.001).  
 Pain can be debilitating after breast cancer treatment and can interfere with the ability to 
carry on with daily activities. In a cross-sectional study by De Groef et al. (2017) on pain 
characteristics and their contribution to upper limb dysfunction in 274 BCS the investigators 
found that pain quality (p = 0.003), pain intensity (p = 0.005), pain catastrophizing (p < 0.001), 
and signs of central sensitization (p < 0.001) contributed to limb dysfunction. Risk factors 
including treatment-related variables, patient-related variables, and impairment-related variables 
were analyzed by bivariable and multivariable analyses. Upper limb function was assessed using 
the Disability of Arm, Shoulder, and Hand (DASH) questionnaire. The mean time after surgery 
was 1.5 years, which reveals that pain resulting from breast cancer treatment can affect long-term 
functioning (i.e. more than one year after surgery). 
A variety of risk factors has been found to contribute to the pain experience in BCS. A 
systematic review of literature and meta-analysis by Leysen et al. (2017) was performed on risk 
factors of chronic pain in BCS. The authors included 17 eligible studies and 17 risk factors for 
		 16	
the development of chronic pain in their meta-analysis. They found that eight (obesity/Body 
Mass Index >30, education <12-13 years, lymphedema, non- or ex-smoker, axillary lymph node 
dissection, chemotherapy, hormone therapy, and radiotherapy) out of 17 risk factors were 
significantly associated (p < 0.05) with increased risk of chronic pain development in breast 
cancer survivorship. Lymphedema was found to be the strongest risk factor (OR: 2.58, 95% CI 
1.93-3.46, p < 0.00001).  
 The etiology of pain is not fully understood. Pain is considered a neurotoxic symptom 
resulting from breast cancer and its treatment. In a study by Lacourt and Heijnen (2017) on the 
mechanisms of neurotoxic symptoms resulting from breast cancer and its treatment, the authors 
found that neuro-inflammation related to stress, cancer treatment, or cancer-related stress is a 
predictor of neurotoxic symptoms such as pain both during and after breast cancer treatment. 
Since stress is commonly experienced by BCS and is often prolonged over a long period of time, 
the stress response is altered and thus stress hormones have a diminished capacity to regulate the 
inflammatory response, leading to neuro-inflammation. The authors also suggested that 
mitochondrial dysfunction results from breast cancer and its treatment, which may potentiate 
neurotoxic symptoms such as pain. It is also suggested that changes in levels of pro- and anti-
inflammatory cytokines and genes associated with their pathways are associated with pain in 
cancer patients. Miaskowski and Aouizerat (2012) found that among cancer patients, pro- and 
anti-inflammatory cytokines and their genes, including IL1B, IL2, IL4, IL6, IL8, and TNF-a are 
potential biomarkers for pain.  
Additional biomarkers that have been found in the literature to contribute to the etiology 
of pain include neurotransmitter (catechols: dopamine, adrenaline, and noradrenaline) and opioid 
receptor dysregulation. Miaskowski and Aouizerat (2012) found that among cancer patients, 
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opioid receptors and neurotransmitters such as COMT and five hydroxtryptamine (5-HT) and 
genes (COMT, 5-HTT, OPMR1) involved in their production pathways, are potential biomarkers 
for pain.  
In summary, pain is a subjective experience that has multiple definitions. It is highly 
prevalent in BCS, distressing, and often affects their quality of life and the ability to carry on 
everyday activities. Its etiology is often misunderstood, however, it is suggested that circulating 
pro- and anti-inflammatory cytokines and genes involved in their pathways, as well as other 
biomarkers including neurotransmitters and opioid receptors, all play a part in the pain 
experience. 
Fatigue. The symptom of fatigue is another main variable in this study. In this section, a 
review of fatigue will be presented, including its definition found in the literature, as well as its 
prevalence among BCS. The etiology of fatigue will also be reviewed. 
Fatigue is a subjective experience and its definition varies in the literature. The Farlex 
Partner Medical Dictionary (2012) defines fatigue as “physical and/or mental exhaustion that can 
be triggered by stress, medication overwork, or mental and physical illness or disease.” A cross-
sectional study by Bower et al. (2000) described fatigue as a subjective feeling of tiredness, 
weakness, and lack of energy, in their article on the occurrence of fatigue and its correlates and 
impact on quality of life in their sample of 1,957 BCS. Additionally, Cleveland Clinic (2017) 
describes fatigue as “a daily lack of energy; an unusual or excessive whole-body tiredness, not 
relieved by sleep.” It is also worth mentioning that cancer-related fatigue has been differentiated 
from fatigue caused by daily life, as cancer-related fatigue is often worse, lasts longer, is 
unpredictable, and increases distress, according to the American Cancer Society (American 
Cancer Society, Cancer Related Fatigue, 2016). Cancer-related fatigue has also been 
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differentiated from healthy fatigue as healthy fatigue, which is more acute and is experienced by 
healthy people in their everyday lives, is relieved by sleep and rest and cancer-related fatigue is 
not (Berger et al., 2010).  
 Fatigue is highly prevalent among BCS. According to the National Cancer Institute 
(2017), up to 82% of BCS report cancer-related fatigue after treatment ends. In a meta-analysis 
of 27 studies including 12,327 BCS by Abrahams et al. (2016), it was found that fatigue 
prevalence was 26.9% (95% CI 23.2-31). Breast cancer survivors at a higher risk for severe 
fatigue following breast cancer treatment include those with stage II or III cancer, and those 
treated with chemotherapy (RR 1.18, 95% CI 1.08-1.28), versus those with stage 0 or I cancer 
and not treated with chemotherapy (RR 1.12, 95% CI 1.06-1.19). In addition, chemotherapy puts 
BCS at a higher risk for severe fatigue. Abrahams et al. (2016) found that BCS who received a 
combination of surgery and radiotherapy had a decreased risk of severe fatigue than those who 
also received additional treatments such as chemotherapy (RR 0.83, 95% CI, 0.70-0.98; RR 0.87, 
95% CI 0.78-0.96). 
Fatigue is suggested to be the result of cancer treatments such as chemotherapy, 
radiation, and aromatase inhibitors (Lacourt & Heijnen, 2017; Schmidt et al., 2015; Vichaya et 
al., 2015). Although the etiology of fatigue is not fully understood, a hypothesis exists that the 
pro-inflammatory cytokine network induces fatigue (DeSanctis et al., 2014; Wang, 2008; Wang 
& Woodruff, 2015), which may be activated by cancer itself, its treatment, and psychosocial 
stress resulting from the cancer experience. Research suggests pro-inflammatory cytokines 
transmit signals to the brain, which in turn facilitate sickness behaviors including fatigue (Lee et 
al., 2004; Wang, 2008; Wang & Woodruff, 2015).  
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Breast cancer survivors have been reported to have increased pro-inflammatory cytokine 
levels, especially more so in those who are also suffering from fatigue. In a cross-sectional study 
by Zick et al. (2014) on differences in inflammatory markers between fatigued and non-fatigued 
BCS, the investigators performed blood analyses on 29 women (16 fatigued and 13 non-
fatigued). Pro-inflammatory cytokine IL-6 was found to be significantly higher (p = 0.03) in 
BCS who were experiencing persistent fatigue versus those who were not. This evidence 
suggests that on a biological level, patients who produce higher levels of IL-6 are more prone to 
experience persistent fatigue after cancer treatment.  
In summary, fatigue is a subjective experience commonly reported by BCS. The 
diagnosis of cancer and its treatment puts BCS at a higher risk of suffering from fatigue. It is 
suggested that increased circulating levels of pro-inflammatory cytokines in the blood induce 
fatigue. 
Genetic polymorphisms associated with pain and fatigue in cancer survivors. 
Genetic polymorphisms are natural variations in DNA sequences that may result in different 
types of characteristics and account for varying perceptions and expressions of pain prevalence 
and/or intensity. Often, what is less painful for one patient may be more painful for another. In 
the following sections, a review of each gene under investigation in this study will be presented, 
including genes COMT, IL6, and IL1B, and their relationships to pain and/or fatigue symptoms 
that have been previously found in other research studies. 
Catechol-O-methyltransferase (COMT). The COMT gene provides instructions for 
producing for catechol-O-methyltransferase enzyme, which is responsible for metabolizing 
catechol neurotransmitters (dopamine, adrenaline, and noradrenaline) in the brain’s prefrontal 
cortex. Within the COMT gene, SNP rs4680 is located on chromosome 22, codon 158, with 
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forward orientation and has been well-studied in its role for the “Warrior vs. Worrier” behavioral 
phenotype and has been associated with pain.  
In the public database available through the National Center for Biotechnology 
Information (NCBI, 2014), the wild-type allele for SNP rs4680 is a (G) and codes for valine 
amino acid, which results in more COMT enzyme available to metabolize catechol 
neurotransmitters and thus less extracellular dopamine in the pre-fontal cortex, and may be result 
in a higher pain threshold and resilience to stress, supporting the “Warrior” behavioral phenotype 
(Stein, Newman, Savitz, & Ramesar, 2006). Adversely, the polymorphic (A) substitution alters 
the amino acid to a methionine. The result of this substitution is 25% of the enzymatic activity 
that a wild-type allele produces, which means less COMT enzyme available to metabolize 
catechol neurotransmitters in the brain and more extracellular dopamine in the prefrontal cortex, 
which may be responsible for lower pain threshold, increased vulnerability to stress, supporting 
the “Worrier” behavioral phenotype (Stein, Newman, Savitz, & Ramesar, 2006).  
Abnormalities in the COMT enzyme activity have been found to contribute to pain. In a 
systematic review and meta-analysis of COMT gene polymorphism and chronic human pain by 
Tammimaki and Mannisto (2012), the authors explored the association between COMT genotype 
and three chronic pain conditions: migraine headaches, fibromyalgia, or chronic widespread pain 
and chronic musculoskeletal pain. The results of their meta-analysis including eight studies 
showed that rs4680 is associated with chronic widespread pain and that the Met allele is a risk 
factor (OR = 1.28, 95% CI 1.06-1.55, p = 0.01, n = 3811).  
In a study by Knisely et al. (2018) on associations between catecholaminergic genes and 
persistent breast pain phenotypes in women following breast cancer surgery, the authors found 
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that each additional copy of C allele for SNP rs4680 in COMT was associated with a 3.34-fold 
increase in the odds of belonging to the Severe Pain Class (p = .028).   
Research by Wang et al. (2015) on the association of SNP rs4680 and pain perception in 
285 cancer patients, participants’ pain level was assessed using the Brief Pain Inventory and 
genotyping using Polymerase Chain Reaction (PCR) analysis was performed. It was found 
through pairwise comparison that COMT wild-type (G) (V108/158M) carriers had higher pain 
scores than heterozygous carriers (CG) (p = .013) and homozygous and variant carriers (CC) (p 
= .003). 
Finally, in a non-cancer population, the major G allele of rs4680 in COMT has been 
found to be associated with an increased severity of chronic postsurgical pain (p = .018) (Rut et 
al., 2014). Participants were asked to rate their pain on a six-point Likert scale in the Oswestry 
Disability Index 12 months after lumbar discectomy. The study reported that the presence of 
major (G) alleles increased pain severity in their sample.  
Other SNPs in gene COMT have been found to be associated with pain as well. A study 
by Lee et al. (2011) found that in their patients undergoing third molar extraction, specific 
genotypes for SNPs rs4818 and rs6269 were associated with postoperative pain. Specifically, 
those with GG genotype reported sufficient postoperative analgesia versus those with AA or AG 
genotype (p < .0001).  
In summary, COMT is an enzyme responsible for neurotransmitter production, and 
variations in SNPs within the gene have been found to affect pain experiences in patients. 
Specific genotypes for SNP rs4680 as well as other SNPs in COMT have been found to result in 
higher or lower pain thresholds in both cancer and non-cancer populations, with mixed results 
for associations between +/- pain severity and (A) and (G) alleles. 
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Interleukin 1 beta (IL1B). The interleukin 1 beta gene provides instructions for 
producing pro-inflammatory IL1B cytokine protein that is an important facilitator for 
inflammation as well as cellular processes including cell proliferation, cell differentiation, and 
cell apoptosis. IL1B has been found to be involved in pain and inflammation (Ren & Torres, 
2009). Within the ILB1 gene, SNP rs16944, also known as “-511,” is located on chromosome 2 
with forward orientation. In the public database available through the National Center for 
Biotechnology Information (NCBI, 2014), the wild-type allele for SNP rs16944 is a (G) while 
the polymorphic allele is an (A). 
In a study by Kober et al. (2016) on the association between SNP rs16944 and fatigue 
levels, the authors evaluated fatigue levels using the Lee Fatigue Scale in (n = 398) and 
performed genotyping in BCS following breast cancer surgery. Results showed that those 
possessing the polymorphic (A) allele of SNP rs16944 in IL1B gene were likely to experience 
higher levels of fatigue than those possessing the wild-type (G). However, in a regression 
analysis, those possessing a GG or AG genotype were found to have a 2.98-fold higher odds of 
scoring higher on the Lee Fatigue Scale those possessing the AA genotype.  
A study of 53 prostate cancer patients by Jim et al. (2012) examined the relationship 
between fatigue and SNP rs16944 in gene IL1B. Fatigue was assessed using the Fatigue 
Symptom Inventory at two time points following androgen deprivation therapy for treatment of 
prostate cancer and genotyping was performed via PCR analysis method. The results were non-
significant for genotype by time interaction for fatigue and SNP rs16944 (p’s > 0.46) 
The results of a study by Collado-Hidalgo et al. (2008) suggest that a variant in SNP 
rs16944 in IL1B predicted fatigue (95% CI = 0.91–16.6, p = .007) in their sample of 47 BCS. 
Fatigue was assessed using the Multidimensional Fatigue Symptom Inventory (MFSI) and DNA 
		 23	
were genotyped using PCR analysis. An association was found between possessing at least one 
cytosine and fatigue (95% CI = 0.91–16.6, p = .007). 
Interleukin 6 (IL6). The interleukin 6 gene provides instructions for producing IL6 
cytokine protein that plays a role in the inflammation response and maturation of B cells. Within 
the IL6 gene, SNP rs1800795, located on chromosome 7 with forward orientation, is also known 
as the “-174 polymorphism.” In the public database available through the National Center for 
Biotechnology Information (NCBI, 2014), the wild type allele for SNP rs1800795 is a (G). 
Research has found that a polymorphic (C) substitution results in less IL6 production in humans 
than those possessing the wild-type allele (G) (Fishman et al., 1998). Pro-inflammatory 
cytokines associated with fatigue have been found to be elevated over a long period of time in 
cancer survivors (Bower, 2014; Bower, Ganz, Aziz, & Fahey, 2002; Collado-Hidalgo et al., 
2006), which suggests that polymorphic (C) individuals may experience less fatigue than those 
with wild-type (G).  
A study by Collado-Hidalgo et al. (2006) assessed the relationship between ex vivo pro-
inflammatory cytokine production and fatigue status among early state BCS. Fatigue status was 
determined using the vitality scale of the SF-36 (score range 0-100, with higher scores indicating 
well-being) and participants were deemed persistently fatigued if their scores were 50 or less 
over two to three time points. Participants with scores greater than 70 were deemed non-fatigued 
and included in the control group. The investigators found that persistently fatigued (N = 32) 
BCS had increased ex vivo monocyte production of IL6 in versus non-fatigued (N = 19) 
following exposure to lipopolysaccharide stimulation (p = .049).   
A more recent study by Collado-Hidalgo et al. (2008) studied single nucleotide 
polymorphisms in the promoter regions of genes associated with pro-inflammatory cytokines IL-
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6 and IL1B and their expressions, to assess their relationships with fatigue status in BCS. 
Participants were screened for fatigue using the SF-36 vitality scale (score range 0-100, with 
higher scores indicating well-being) and women with scores of 50 or less were deemed fatigued 
and placed in the experimental group (N = 33) while women with scores of 70 or higher were 
placed in the non-fatigued control group (N = 14). The Multidimensional Fatigue Symptom 
Inventory was then used to confirm fatigue symptoms. The investigators extracted genomic 
DNA from peripheral blood leukocytes and amplified by polymerase chain reaction technique 
and genotypes were analyzed using chi-square and multivariate logistic regression analyses. 
Results showed that homozygosity for either GG or CC variant of the IL6 −174 genotype 
(p = .027) predicted fatigue. 
 A study by Bower et al. (2013) on variations in genes responsible for cytokine 
production and fatigue among 171 BCS found statistically significant associations between 
genetic risk scores involving SNP rs1800795 in IL6 gene and fatigue severity. Fatigue was 
measured using the Multidimensional Fatigue Symptom Inventory (Short Form). The authors 
hypothesized that polymorphisms in pro-inflammatory cytokine genes regulate expression and 
therefore predict fatigue severity in BCS after the completion of cancer treatment. They found 
that genetic risk score was significantly associated with fatigue (p = .002) with a small to 
medium effect size (r = 0.22). Subjects possessing the GG genotype reported higher levels of 
fatigue than those possessing the GC or CC genotype. 
A study by Jim et al. (2012) on genetic predictors of fatigue in 53 prostate cancer 
patients, it was found that those possessing the GC or CC genotype of SNP rs1800795 of IL6 
gene reported increased fatigue intrusiveness, frequency, and duration than those possessing the 
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GG genotype (p < .05). In their study, fatigue was assessed using the Fatigue Symptom 
Inventory and DNA were genotyped via PCR analysis.  
In a prospective, cross-sectional study by Shi et al. (2014) on the association between 
SNP rs1800795 in IL6 and risk of persistent symptom burden in multiple myeloma patients, 
patients rated the severity of 13 cancer-related symptoms from the MD Anderson Symptom 
Inventory (MDASI) and their DNA were genotyped using PCR analysis. Of the 344 patients 
included in the analysis, the two most commonly reported physical symptoms included fatigue 
(47%) and pain (42%). For non-Hispanic whites, which comprised most of the sample (n = 222), 
GG genotype predicted less severe fatigue (OR, 0.53; 95% CI, 0.29-0.88; p = .013) and in other 
ethnicities, GG genotype predicted more severe pain (OR, 3.36; 95% CI, 1.23-13.64; p = .010). 
In summary, alterations in COMT activity as well as circulating levels of IL1B and IL6 
have been previously found in the literature to affect pain and fatigue symptoms in cancer 
survivors. Variations in genotypes among genes associated with COMT, IL1B, and IL6 
production have also been found to influence pain and fatigue reported by cancer survivors. The 
findings have been mixed, which warrants further investigation of specific genotypes that may 
moderate symptoms in these populations. 
Mind-body interventions and their impact on pain and fatigue in BCS. Multiple 
mind-body interventions exist in the literature for management of pain and fatigue symptoms 
that BCS experience after curative treatment. In 2017, the American Cancer Society updated 
clinical practice guidelines set forth by The Society for Integrative Oncology in 2014, for 
integrative treatments during and after breast cancer treatment (Greenlee et al., 2017), and the 
recommended mind-body therapies for the post-treatment management of fatigue and pain are as 
follows: 
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1. Acupuncture and yoga can be considered for improving post-treatment fatigue (Grade C 
Recommendation). 
2. Acupuncture, healing touch, hypnosis, and music therapy can be considered for the 
management of pain (Grade C Recommendation). 
Additional mind-body therapies that have been found effective for reducing fatigue in 
cancer include Mindfulness-Based Stress Reduction (MBSR) (Carlson & Garland, 2005), the 
Mindfulness-Based Stress Reduction for Breast Cancer program (MBSR(BC)) (Lengacher et al., 
2009, 2011, 2015a,b,c, 2016; Reich et al., 2017a), meditation (Dobos et al., 2015), yoga (Bower 
et al., 2011), tai chi (Galantino et al., 2003; Larkey, Huberty, Pedersen, & Weihs, 2016; Rausch, 
Robins, Walter, & McCain, 2006; Mustian et al., 2004), acupressure (Rosenberg, 2016), and 
acupuncture (Dean-Clower et al., 2010).  
Mind-body therapies that have been found effective for reducing pain in cancer include 
acupressure (Yeh et al., 2017), acupuncture (Tao et al., 2016; Yang et al., 2017), hypnosis 
(Montgomery et al., 2007, 2002), yoga and tai chi (Yang et al., 2017), healing touch (Post-White 
et al., 2003; FitzHenry et al., 2014), music therapy (Binns-Turner, Wilson, Pryor, Boyd, & 
Prickett, 2011; Li, Zhou, Yan, Wang, & Zhang, 2012), meditation (Dobos et al., 2015), 
Mindfulness-Based Stress Reduction (Johns et al., 2016), and Mindfulness-Based Stress 
Reduction for Breast Cancer (Kvillemo & Branstrom, 2011). 
 Mindfulness-based stress reduction (MBSR). Since its development at the University of 
Massachusetts Medical Center by Dr. Jon Kabat-Zinn in the 1970’s, MBSR has become an 
increasingly popular therapy to assist patients with a wide variety of conditions (Kabat-Zinn, 
1985, 1994). The goal of MBSR is to “maintain awareness moment by moment, disengaging 
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oneself from strong attachment to beliefs, thoughts, or emotions and thereby developing a greater 
sense of emotional balance and well-being” (Ludwig & Kabat-Zinn, 2008, p. 1350). 
Studies have proven mindfulness-based stress reduction as an effective therapy for BCS 
experiencing adverse symptoms after cancer treatment ends. A study by Lengacher et al. (2016) 
found that a 6-week Mindfulness-Based Stress Reduction for Breast Cancer program improved a 
broad variety of symptoms in their randomized controlled trial of 322 BCS. Compared to UC, 
those who received the intervention demonstrated improvement in both psychological symptoms 
of anxiety and fear of recurrence, and physical symptoms including fatigue severity and fatigue 
interference (p < .01). It was also found that the largest effect sizes included those for fear of 
recurrence (d = 0.35) and fatigue severity (d = 0.27).  
Lengacher et al.’s (2014) randomized controlled trial of 82 BCS who were randomly 
assigned 1:1 to either a six-week MBSR(BC) program (N = 40) or control group (N =42) 
reported that participants who received the intervention experienced favorable changes in the 
symptoms they experienced after breast cancer treatment. Improvements were found among five 
potential mediators: (1) the change in fear of recurrence mediated the effect of MBSR(BC) on 
the six-week change in perceived stress (z = 2.12, p = 0.03) and state anxiety 
(z = 2.03, p = 0.04); and (2) the change in physical functioning mediated the effect of 
MBSR(BC) on the six-week change in perceived stress (z = 2.27, p = 0.02) and trait anxiety 
(z = 1.98, p = 0.05). 
In a randomized controlled pilot study by Johns et al. (2014) on MBSR for persistently 
fatigued cancer survivors, 37 participants were randomly assigned in a 1:1 ratio to either a seven-
week MBSR program or a waitlisted control group and were followed for six months post-
intervention. Cancer survivors who received the MBSR intervention reported greater reductions 
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in fatigue interference (d = -1.43, p < 0.001) and fatigue severity (d = -1.55, p < 0.001) than the 
control group, which were assessed at baseline, post-intervention, one-month follow-up, and six-
month follow-up using the Fatigue Symptom Inventory. 
 Research has also focused on not only MBSR itself, but also how it compares to other 
interventions aimed at treating adverse symptoms after cancer treatment. In a study by Johns et 
al. (2016,a) of 71 breast and colorectal cancer survivors comparing MBSR to psychoeducational 
support, the authors did not find a significant improvement in cancer-related fatigue after the 
intervention, however, they did report a trend favoring MBSR (p = 0.073) at one time point. 
They also reported a significant effect size in vitality (p = 0.003) at the same time point. The 
group who received MBSR also reported higher satisfaction with their intervention than the 
psychoeducational support group (M=8.7 and M=8.4, respectively).  
A meta-analysis by Huang, He, Wang, and Zhou (2016) of 964 BCS in nine articles 
reported that compared to control groups, those who receive mindfulness-based stress reduction 
have statistically significant improvements in depression, anxiety, and stress (p’s < 0.00001) and 
increased quality of life (p = 0.03).  
Mindfulness-based stress reduction has also been found to have a positive effect on sleep, 
as evidenced by a randomized controlled trial by Lengacher et al. (2015c) in BCS. In their study, 
79 participants were randomly assigned to either the intervention group (MBSR(BC)) or UC. 
Using subjective sleep assessments, such as a sleep diary and the Pittsburgh Sleep Quality Index, 
and objective sleep assessments, such as actigraphy, it was indicated that the MBSR(BC) 
program had greater positive effects on objective sleep parameters involving sleep efficiency (p 
= 0.04), time spent sleeping (p = 0.02), and less waking periods (p < 0.01), than the UC group at 
a 12-week follow-up after the intervention. 
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Mindfulness-based stress reduction has also been found to be effective in treating 
symptom clusters, defined as multiple concurrent and related symptoms “that are not required to 
have a shared etiology” (Dodd, Miaskowski, & Paul, 2001, p.465). In Lengacher et al.’s (2012) 
study of symptom clusters in 322 BCS, results indicated that mindfulness-based stress reduction 
modestly improved fatigue and sleep disturbances. Further, Reich et al.’s (2017a) study of 
immediate and sustained effects of the Mindfulness-Based Stress Reduction for Breast Cancer 
program found that mindfulness-based stress reduction improved clusters of symptoms in BCS at 
the six-week assessments, particularly for fatigue and psychological clusters, showing immediate 
effects.  
Mindfulness-Based Stress Reduction has been found to be a cost-effective and therapy 
for BCS. In a study by Lengacher et al. (2015a), the authors noted that cost for increased quality 
of life per year was relatively low compared to other breast cancer interventions found in the 
literature. Mindfulness-Based Stress Reduction has been adapted to a mobile intervention for 
BCS, to provide an at-home accessible solution to those who find it difficult to travel.  
Mindfulness-based stress reduction has also been found to be an accessible therapy for 
BCS. In a pilot study by Lengacher et al. (2017), a six-week Mindfulness-Based Stress 
Reduction for Breast Cancer program was adapted to mobile delivery of the intervention among 
15 participants. Thirteen participants completed the study and the results showed that there were 
significant improvements in both psychological (depression, anxiety, stress, fear of recurrence) 
and physical symptoms (sleep quality and fatigue) and quality of life (p's < 0.05). 
 It has been shown that Mindfulness-Based Stress Reduction may also improve immune 
recovery during breast cancer management, as evidenced by four studies found in the literature. 
A randomized controlled trial of 82 breast cancer patients was conducted by Lengacher et al. 
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(2013). Participants were randomized to either a mindfulness-based stress reduction or control 
group. Immunological biomarkers were analyzed at baseline and within two weeks post-
intervention and it was found that women who received the intervention experienced a faster 
recovery of functional T cells.  
In addition, Reich et al. (2014) also found a positive relationship between immune 
recovery markers and Mindfulness-Based Stress Reduction, with a regression model that found 
predictors of gastrointestinal improvement included B-lymphocytes and interferon-γ as the (p < 
.01), predictors of cognitive and psychological improvements included +CD4+CD8 (p = .02), 
and predictors of fatigue symptom improvement included lymphocytes and IL-4 (p < .01). 
Another study by Reich et al. (2017b) of 322 BCS found that a Mindfulness-Based Stress 
Reduction for Breast Cancer program affected cytokine levels, particularly in increasing levels of 
TNFa and IL-6, markers of immune recovery. At baseline of the study, it was found that IL6 
cytokine levels varied according to type of cancer treatment, and negative correlations were 
found between patients who received mastectomy (versus lumpectomy) and chemotherapy, 
meaning they experienced lower levels of IL6 (p < .05). Participants who had received radiation 
experienced higher levels of IL6 (p < .01). Compared to control group participants, patients in 
the MBSR(BC) intervention group experienced higher increases in plasma levels of IL6 (p = .05) 
over the 12-week period of the study, versus the control group. It was suggested that MBSR(BC) 
supports immune system restoration in BCS. 
Lastly, another randomized controlled trial by Sarenmalm, Martensson, Andersson, 
Karlsson, and Bergh (2017) on the effects of Mindfulness-Based Stress Reduction on immune 
function in 177 BCS, it was found that natural killer cell activity (p = 0.015) and CD3+T	and 
CD3+8+T-lymphocyte activity shifted (p = 0.027 and p = 0.035, respectively), in which the 
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authors suggested that this biological response was consistent with study by Fang et al. (2010), 
showing that increased post-Mindfulness-Based Stress Reduction well-being was associated with 
a shift in natural killer activity.  
Mindfulness-Based Stress Reduction has recently entered into the personalized medicine 
arena, with genetic a study by Lengacher et al. (2015b) on cognitive impairment and 
MBSR(BC). Their two-armed randomized controlled trial tested whether 10 SNPs in eight genes 
known to be associated with cognitive function were associated with cognitive impairment in 
their sample of 72 participants, and if the SNPs moderated the effects of the Mindfulness-Based 
Stress Reduction for Breast Cancer program on cognitive impairment, versus a UC group. 
Participants (mean age 58 years) were randomized 1:1 to either a six-week MBSR(BC) program 
or UC and cognitive impairment was assessed at baseline, six weeks, and 12 weeks, using the 
Everyday Cognition (ECog) questionnaire. The ECog is a 40-item self-report questionnaire that 
asks patients to compare everyday functioning on a 4-point scale at the present moment versus 
10 years ago (1 = better or no change, to 4 = consistently much worse). DNA samples extracted 
from their blood were used to genotype using TaqMan allele discrimination polymerase chain 
reaction (PCR). The results showed that SNPs in four genes (ANKK1, APOE, MTHFR, SLC6A4) 
were associated with cognitive impairment. In addition, a single nucleotide polymorphism, 
rs1800497 in gene ANKK1, moderated the effects of the Mindfulness-Based Stress Reduction for 
Breast Cancer program on cognitive impairment. Specifically, participants carrying the 
polymorphic AA or AG genotype received more benefit than those carrying the wild-type (GG) 
genotype. To this date, there are currently no studies examining patient outcomes involving 
genetic influence on pain and fatigue symptom improvement resulting from MBSR(BC). 
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Research has shown MBSR(BC) as a mind-body therapy that has been proven to be 
effective for treating individual symptoms experienced by BCS, including anxiety, depression, 
stress, fatigue, and sleep, as well as symptoms that occur in clusters and cognitive impairment. It 
has been found in the literature that MBSR affects biomarkers including circulating cytokines, 
and has recently entered the realm of precision medicine with a study that found genetic 
moderation of cognitive impairment in BCS participating in a MBSR(BC) program. 
Summary 
 In summary, fatigue and pain are commonly reported by BCS. Findings from the 
literature identify fatigue and pain as highly prevalent among BCS, which negatively affects their 
quality of life and the ability to function in everyday activities. Fatigue and pain symptoms have 
been associated with biomarkers in the body, including pro- and anti-inflammatory cytokines 
such as IL1B and IL6, and the enzyme COMT, in which genes associated in their pathways are 
under investigation in this study. Previous research found in this review of literature has 
identified associations between pain and fatigue symptoms and genetic variations in subjects 
experiencing such symptoms. Mind-body interventions such as MBSR(BC) have been proven 
effective at treating multiple symptoms experienced by BCS and has recently entered the 
precision medicine arena.  
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Chapter Three 
Methods 
Introduction 
Chapter three explains the methods and procedures for this study. The purpose of this 
study was to identify specific genotypes involved in fatigue and pain symptoms and explore 
whether SNP rs16944 in gene IL1B, SNP rs4680 in gene COMT, and SNP rs1800795 in gene IL6 
moderate fatigue and/or pain outcomes in BCS and whether the effects of the MBSR(BC) 
intervention on fatigue and/or pain are moderated by these SNPs. This chapter first provides 
detailed information regarding the research design, setting, and sample for this genetic research, 
which was conducted within the R01 MBSR Symptom Cluster Trial for Breast Cancer Survivors. 
Next, the instruments used to measure each outcome variable will be detailed, followed by the 
procedures and data analyses used. 
Research Design 
This research study was partially funded by a grant awarded by Sigma Theta Tau 
International Honor Society of Nursing, Delta Beta-at-Large chapter and was conducted in part 
as a secondary data analysis within the parent study, MBSR Symptom Cluster Trial for Breast 
Cancer Survivors/ R01CA131080. This parent R01 study used a two-group randomized design, 
with 1:1 ratio assignment of BCS to either: (1) a six-week MBSR(BC) program, or (2) Usual 
Care (Figure 1). Randomization was stratified by: (1) type of breast cancer surgery (lumpectomy 
vs. mastectomy); (2) breast cancer treatment (chemotherapy with or without radiation vs. 
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radiation alone); and (3) stage of cancer at diagnosis (0-III). The current study implemented 
additional analyses of stored biological DNA samples and physical symptom measurement data 
to explore pain and fatigue outcomes resulting from the MBSR(BC) intervention and their 
possible genetic moderating effects. 
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Figure 2. Consolidated Standards of Reporting Trials (CONSORT) flow diagram of participant 
screening, enrollment and allocation from parent R01 trial to study subset.  
Setting. Participants were recruited from the Carol and Frank Morsani Center for 
Advanced Health as well as Moffitt Cancer Center, both located in Tampa, Florida. The 
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assessments and delivery of the intervention took place at the Survivorship Clinic of the Moffitt 
Cancer Center and Research Institute. Genotyping was performed at the laboratory of Dr. Jong 
Park at Moffitt Cancer Center and Research Institute. 
Population and Sample. The primary inclusion criteria for this study were: 1) women 
age 21 or older who had been diagnosed with stage 0-III BC who had undergone lumpectomy 
and/or mastectomy, 2) were at least two weeks but no more than two years from end of cancer 
treatment with adjuvant radiation and/or chemotherapy. Exclusion criteria included: 1) patients 
diagnosed with stage IV BC, 2) self-reported a severe current psychiatric diagnosis (e.g. bipolar 
disorder), or 3) recurrent BC. Out of 322 women who participated in the parent R01 Symptom 
Cluster Trial for Breast Cancer Survivorsstudy, 158 (MBSR(BC) = 75; UC = 83) consented for 
genetic study with their DNA, and were included in this study. 
Measurements  
 Demographic survey.  Demographic data were collected from participants and included 
age, sex, gender, race, ethnicity, marital status, income status, highest level of education 
completed, and employment status (see Appendix A).  Demographic data were gathered at 
baseline and updated at six and 12 weeks.  A chart audit was completed through use of medical 
records to verify all medical and treatment information.   
 Clinical history survey.  A Standard Clinical History form was collected at baseline and 
updated at six and 12 weeks to determine if there were any new problems and treatment related 
to problems.  Data collected included types of cancer treatment, medications, stage of cancer 
diagnosis, date treatment ended.  
 Brief Pain Inventory.  Pain was measured by the Brief Pain Inventory (BPI), which was 
developed to assess pain related to cancer and gives patients the ability to rate their pain severity 
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and the extent to which it interferes with dimensions of feeling and ability to function (Cleeland, 
2009). The BPI (see Appendix B) contains 9-items that examine pain intensity and interference 
in patients (Keller et al., 2004).  Items 1-6 assess pain type, pain location, and pain severity 
during the past week, on average and at present.  Items 7-8 refer to medications and their 
usefulness in relieving pain.  Item 9 assesses the severity of pain interference in patients’ daily 
activities.  Reliability coefficients for the BPI Severity and Interference scales were high with 
reliability coefficients ranging from .82 to .95.   
 Fatigue Symptom Inventory. Fatigue was measured by the Fatigue Symptom Inventory 
(FSI).  The FSI (see Appendix C) is a 14-item self-report measure designed to assess fatigue 
severity, its frequency, and its daily pattern (Hann et al., 1998; Hann, Deniston, & Baker, 2000; 
Stein & Jacobsen, 1998).  Items include 4 indicators of fatigue experienced in the past week and 
are measured on separate 11-point scales (0=Not at all fatigue; 10=Extreme fatigue) as well as 
current fatigue.  Perceived interference is a seven-item subscale that uses separate 11-point scales 
to assess fatigue’s interference with daily activities and was found to have good internal 
consistency with alpha coefficients ranging from 0.93-0.95 (Radiation Therapy Oncology Group, 
2010).  Convergent validity was demonstrated by significant positive correlations measures 
between the FSI and (POMS-Fatigue Scale) and significant negative correlations between the 
FSI and measures of psychological functioning (e.g., SF-36 Health Survey).  Reliability 
coefficients for the FSI were high at >.90. 
 Candidate gene and single nucleotide polymorphism selection. Candidate genes and 
SNPs were chosen to represent polymorphisms in genes involved in various pathways, including 
fatigue and pain function using PubMed database. Selected genes examined in these pathways 
include COMT, IL1B, and IL6. Once candidate genes were confirmed, SNPs were selected based 
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on their previous associations with gene transcription or protein activity related to pain via 
COMT (Barbosa et al., 2012; Fijal, Perlis, Heinloth, & Houston, 2010; Finan et al., 2011; 
Jacobsen et al., 2012; Kim et al., 2006; Omair et al., 2012; Martinez-Jauand et al., 2013; Nicholl 
et al., 2010; Rakvag et al., 2008; Smith et al., 2014; Tammimaki & Mannisto, 2012; Vargas-
Alarcon et al., 2007; Wang et al., 2015; Zubieta et al., 2003) and IL6 (Branford, Droney, & Ross, 
2012; Kovacs et al., 2016; Reyes-Gibby et al., 2008), and fatigue via IL1B (Bower et al., 2013; 
Jim et al., 2012; Reinertsen et al., 2011). 
Procedures 
 Approvals. This study was approved by the University of South Florida Institutional 
Review Board and Scientific Review Committee for Moffitt Cancer Center  
 (IRB #Ame12_107408) (see Appendix D). All policies for the University of South Florida 
Institutional Review Board and Scientific Review Committee for Moffitt Cancer Center were 
adhered to.  
 Recruitment.  Potential participants who met the inclusion criteria were recruited from 
the breast cancer treatment center clinics at the Moffitt Cancer Center and Research Institute and 
USF’s Carol and Frank Morsani Center for Advanced Healthcare.  Health practitioners were 
provided with a complete description of the study aims and protocol.  Consistent with current 
HIPAA regulations, patients were contacted by Moffitt members and health practitioners who 
identified eligible patients during routine patient care, and they provided a brief overview of the 
MBSR(BC) study.  Multiple recruitment methods were used.  To maintain consistency in 
participant recruitment, the recruiters followed a template to describe the study.  Second, 
advertisements were placed in Moffitt Cancer Center and Research Institute, which included 
flyers and brochures. A log was implemented to track contacts made between the study recruiters 
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and potential participants. Interested patients who met the study inclusion criteria were asked to 
sign a form to show their interest in participating in the study.  
 Informed consent. Patients who were interested in the study were invited to an in-person 
orientation session, in which the principal investigator or the research assistant explained the 
details of the study and requirements to participate and combined HIPAA and consent 
documents were obtained. To maximize enrollment and minimize patient dropout, the principal 
investigator emphasized that, regardless of random assignment, all participants would be able to 
participate in the MBSR(BC) program and if they were assigned to UC, the program would be 
available following a wait period.  Moreover, it was emphasized that the timing of the 
intervention was selected to assist in the critical transition period when formal medical care and 
support had ended, which was at least two weeks but not more than two years after cancer 
treatment ended.  Details of the study were reviewed with the patients, including the six-week 
schedule of the MBSR(BC) program, information about the blood draw, and the three time 
points for the questionnaires to be completed. Consent was obtained from all study participants.  
 Data collection procedures. An in-person collection of demographic data, clinical 
history data, the Fatigue Symptom Inventory, and Brief Pain Inventory, were performed at 
baseline, the end of the six-week intervention, and follow-up at 12 weeks, which were collected 
from all participants who agreed to participate in the study. Five milliliters of blood were drawn 
at baseline from the 158 participants who consented for genetic analyses and were part of this 
study. Genomic DNA were isolated from peripheral blood leukocytes with a Qiagen DNA 
extraction kit (Qiagen, Valencia, CA) with modifications, and stored at Dr. Jong Park’s 
laboratory at Moffitt Cancer Center and Research Institute. For this dissertation study, 
genotyping was performed using the stored DNA. A total of three candidate SNPs in three genes 
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(rs1800795 in IL6, rs16944 in IL1B, rs4680 in COMT) were found to be associated with fatigue 
and pain symptoms during a literature review and a preliminary study (Lengacher et al., 2015b). 
DNA samples from blood were genotyped using TaqMan allele discrimination PCR analysis 
method. Different probes were used in the PCR analysis to determine between variant DNA 
sequences at a single locus. In short, PCR reactions were performed using both 96-well and 384-
well plates on separate occasions. The 96-well plates were prepared by combining 10µL TaqMan 
Universal PCR Master Mix, 0.5µL primer, 5.5µL RNA-free water, and 4µL DNA, for a total of 
20µL per well. The 384-well plates were prepared by combining 5µL TaqMan Universal PCR 
Master Mix, 0.25µL primer, 2.75µL RNA-free water, and 2µL DNA, for a total of 10µL per 
well. PCR was performed for 45 amplification cycles using the ABI Prism 7900HT. Sequence 
Detection System (SDS) version 2.3 was used to distinguish between wild-type and polymorphic 
alleles by identifying homozygous wild-type, homozygous variant, or heterozygous genotype 
alleles. Assays included two controls and five duplicates as part of quality control.  
 Description of intervention. The MBSR(BC) program is a six-week complementary 
alternative medicine program adapted and tested by Lengacher et al. (2009) from Dr. Jon Kabat-
Zinn’s original eight-week program aimed at reducing stress through self-regulation of 
symptoms to improve the quality of life in BCS (Lengacher et al., 2009). The intervention 
components consist of: 1) educational material, 2) formal and informal meditative practice 
techniques, and 3) group processes related to barriers to the practice of meditation and the 
application of mindfulness in daily situations (Lengacher et al., 2009).  Participants received 
training in four types of meditation techniques including: 1) sitting meditation, 2) body scan, 3) 
Gentle Hatha Yoga, and 4) walking meditation. Subjects assigned to the MBSR(BC) group were 
scheduled for six weekly sessions lasting two hours each, which were conducted by a group 
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leader trained in MBSR(BC).  Class sizes consisted of five to six participants.  In addition to the 
repeated assessment of blood studies and psychological symptoms, physical symptoms, quality 
of life and mediators at 6 and 12 weeks. MBSR(BC) participants were also asked to record their 
formal meditation practice times in a daily diary during the intervention period as well as during 
the following six-week period after the end of the intervention. 
 The UC group consisted of standard post-treatment follow-up clinic visits and 
participants were asked to abstain from meditation or yoga techniques.  Usual care participants 
were waitlisted to the MBSR(BC) intervention, giving them the ability to participate in the 
MBSR(BC) program after study end (after 12 weeks). 
 Data management. The statistical software used for data entry, management, and 
analysis was Statistical Package for Social Sciences (SPSS) version 25. All data were de-
identified and in order to maintain patients’ confidentiality, password-protected files were stored 
in Dr. Cecile Lengacher’s office, the principle investigator of the parent study.  
Data Analysis 
 Sample characteristics were analyzed using descriptive statistics and frequency 
distributions generated from SPSS.  Chi-Square tests were used for categorical variables and t-
tests were used for continuous variables, to identify any potential differences between groups not 
controlled for by randomization. 
 Aim #1: To identify specific genotypes involved in fatigue and pain symptoms.  
First, to identify specific genotypes that are significantly associated with fatigue and/or pain 
symptoms at baseline, a one-way linear trend ANOVA was performed in SPSS for each SNP. 
 Aim #2: To explore whether single nucleotide polymorphism (SNP) rs1800795 in gene 
IL6, SNP rs16944 in gene IL1B, and SNP rs4680 in gene COMT, moderate the effects of the 
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MBSR(BC) intervention on fatigue and/or pain symptoms, a comparison of mean scores on 
Fatigue Symptom Inventory and Brief Pain Inventory subscales over time at three time points 
(baseline, 6 weeks, 12 weeks) for each SNP were first examined. A mixed model (MBSR(BC) X 
time) approach was then performed. Single nucleotide polymorphism variables and MBSR(BC) 
were analyzed as main effects along with the interaction of MBSR(BC) x SNP and MBSR(BC) x 
SNP x time (baseline to 12 weeks).  A statistically significant interaction between MBSR(BC) x 
SNP on the slope of symptom change indicates that the relationship between MBSR(BC) and 
symptoms varies as a function of SNPs.  Because we proposed to test a specific intervention 
(MBSR(BC)) and multiple SNPs in genes with multiple outcomes, a false discovery rate (FDR) 
approach was used.  Given the potential for multiple comparisons of three SNPs in three genes 
associated with pain and fatigue from a literature review, an FDR rate of 0.10 was adopted.  This 
value means that 10% of the rejected null hypotheses were assumed to be type 1 errors 
(Benjamini & Hochberg, 1995).  
 Statistical power. Since the sample size among different races may lack precision, the 
analyses were limited to Caucasians due to the insufficient number of minorities. A sample size 
of 158 subjects provides 80% power with 2-sided type I error rate of 0.05 to detect an effect size 
of 1.2 for the two-way interactions between genotype x time, genotype x assignment 
(MBSR(BC) versus UC), and assignment x time, analyzed in SPSS using linear mixed models 
from Aim 2. As these analyses were not designed to be confirmatory, no correction procedure 
was used for the type I error rate. 
 Methodological issues and limitations. Due to the modest sample size of 158 patients 
(MBSR(BC) n = 75; UC n = 83), the identification of SNPS associated with fatigue and/or pain 
symptoms and the degree to which they potentially moderate the effects of the MBSR(BC) 
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program may be subject to uncertainty. However, for Aims 1 and 2, the analysis should not be 
considered confirmatory, but rather as providing insight into the extent to which specific SNPs 
may modify the effectiveness of the MBSR(BC) program in reducing levels of pain and fatigue.  
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Chapter Four 
Results 
Introduction 
 This chapter presents the results of the study. First the descriptive characteristics of the 
sample are presented, followed by the study findings for Aim 1 and Aim 2 identifying specific 
genotypes associated with fatigue and pain outcomes after breast cancer treatment and exploring 
whether specific genotypes moderated the effects of MBSR(BC) on fatigue and pain outcomes.  
Participant Characteristics 
 The sample consisted of 158 BCS from the original 322 BCS enrolled in the R01 
Symptoms Cluster Trial for Breast Cancer Survivors/1R01CA131080, for which DNA had been 
collected. Participants were enrolled into the study and were randomly assigned to either the 
MBSR(BC) or UC group using computer-generated randomization, which randomly assigned 
participants stratified by stage of cancer (Stages 0-III) and type of cancer treatment (lumpectomy 
versus mastectomy and radiation with or without chemotherapy). Among the 158 participants, 
there were no significant differences in age, stage of cancer, or type of cancer treatment, between 
the MBSR(BC) (n = 75) and UC (n = 83) groups. However, there were significantly more (p = 
.04) participants in the UC group (83.1%) within one year from end of cancer treatment 
compared to the MBSR(BC) group (69.3%) (see Table 3). 
 Baseline demographic comparisons were produced for all 158 participants. Furthermore, 
fatigue and pain symptom data were complete for all 158 participants at baseline, six weeks, and 
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the 12-week follow-up. All 158 participants completed the study data points. Baseline 
demographics are illustrated in Table 1. Chi-Square tests were used for categorical variables and 
t-tests were used for continuous variables (i.e. age), to identify any potential differences between 
groups not controlled for by randomization. 
 The mean age for the total sample was 58.4 years, with the mean age for the MBSR(BC) 
group being 58 years and 58.7 years for the UC group. The majority of participants were white, 
non-Hispanic (89%), and differences between groups were similar, with the MBSR(BC) group 
being 89% White, non-Hispanic and the UC group being 88% white, non-Hispanic. There were 
no significant differences (p > .05) between the MBSR(BC) and UC groups on any of the 
demographic characteristics for age and race/ethnicity. The majority (70.9%, n=112) of 
participants in the sample were married and this was similar between groups, with 72% (n=54) of 
participants being married in the MBSR(BC) group, and 69.9% (n=58) being married in the UC 
group. The total sample’s education status was mostly college educated, with 75.3% at least 
having some college education or an associate’s degree. Approximately two-thirds of the 
participants were unemployed (n=100, or 63.3%), while approximately one-third (n=58, or 
36.7%) were working either part time (<32 hours per week) or full time (>32 hours per week). 
Among the MBSR(BC) group, 33.3% (n=25) were employed, while 39.8% (n=33) of the UC 
group were employed. Finally, the majority of the sample included those with an annual 
household income of $40,000 to less than $80,000 (29.1%), and there were no statistically 
significant differences (p = .905) between groups for annual household income. Three subjects 
declined to report their income, for a total of 2% missing values. 
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Table 1. Baseline Demographics (Age, Race/Ethnicity, Marital Status, Education Status, 
Employment Status, and Annual Household Income of Participants) By Randomization 
Assignment by Frequency and Percent 
Variable Total 
N=158 
MBSR(BC) 
n=75 
Usual Care 
n=83 
p value 
Mean Age + Standard Deviation 
(years) 
 
Race, Ethnicity 
White, non-Hispanic 
White, Hispanic 
 
Marital Status, n (%) 
Married 
Divorced 
Single 
Widowed 
Other 
58.4±9 
 
 
 
140 (89%) 
18 (11%) 
 
 
112 (70.9%) 
5 (3.2%) 
16 (10.1%) 
21 (13.3%) 
4 (2.5%) 
58±10 
 
 
 
67 (89%) 
8 (11%) 
 
 
54 (72%) 
2 (2.7%) 
7 (9.3%) 
9 (12%) 
3 (4%) 
 
58.7±8 
 
 
 
73 (88%) 
10 (12%) 
 
 
58 (69.9%) 
3 (3.6%) 
9 (10.8%) 
12 (14.4%) 
1 (1.3%) 
.904 
 
 
.948 
 
 
 
.805 
 
 
Education Status, n (%) 
 
 
   
.803 
No College 
   Some Grade School 
   Some High School 
   High School Graduate 
   Vocational/Technical School 
Some College 
College 
Graduate or Professional School 
 
 
1 (0.6%) 
3 (1.9%) 
26 (16.5%) 
9 (5.7%) 
45 (28.5%) 
41 (25.9%) 
33 (20.9%) 
 
 
1 (1.3%) 
2 (2.7%) 
11 (14.7%) 
4 (5.3%) 
19 (25.3%) 
20 (26.7%) 
18 (24%) 
 
0 (0%) 
1 (1.3%) 
15 (18.1%) 
5 (6%) 
26 (31.3%) 
21 (25.3%) 
15 (18.1%) 
 
Employment Status, n (%) 
Employed  
Unemployed 
 
58 (36.7%) 
100 (63.3%) 
 
25 (33.3%) 
50 (66.7%) 
 
33 (39.8%) 
50 (60.2%) 
.812 
 
 
 
Annual Household Income, n 
(%) 
<$10,000 
$10,000 to $19,999 
$20,000 to $39,999 
$40,000 to $79,999 
$80,000 to $99,999 
>$100,000 
Declined to Report 
 
19 (12%) 
25 (15.8%) 
31 (19.6%) 
46 (29.1%) 
13 (8.2%) 
21 (13.3%) 
3 (2%) 
 
9 (12%) 
13 (17.3%) 
12 (16%) 
24 (32%) 
6 (8%) 
10 (13.3%) 
1 (1.4%) 
 
10 (12%) 
12 (14.4%) 
19 (22.9%) 
22 (26.5%) 
7 (8.4%) 
11 (13.3%) 
2 (2.5%) 
.905 
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 The results related to clinical characteristics (stage of disease, surgery type, treatment 
type, and time since treatment) for the participants in the total sample, as well as comparisons of 
the MBSR(BC) and UC groups, are displayed in Table 2. Cancer staging for the total sample 
included Stage 0, n=18 (11.4 %); Stage I, n=61 (38.6 %); Stage II, n=54 (34.2 %); and Stage III, 
n=25 (15.8 %). There were no statistically significant differences (p = .67) between groups. The 
treatment breakdown included 13.9% (n=22) of total sample participants having chemotherapy 
only, 25.9% (n=41) had radiation only, 30.4% (n=48) had a combination of chemotherapy and 
radiation, and 29.7% (n=47) had no chemotherapy or radiation. There was no statistically 
significant difference (p=.905) between the MBSR(BC) and UC groups for cancer treatment. The 
majority of total sample participants were treated surgically by mastectomy (n=93, or 58.9%) 
versus lumpectomy (n=65, or 41.1%). There was similarity between groups, with 61.5% (n=51) 
of UC and 56% (n=42) of MBSR(BC) participants treated by mastectomy and 38.5% (n=32) of 
UC and 44% (n=33) of MBSR(BC) participants treated by lumpectomy there was no statistically 
significant difference between groups (p = .487). Descriptive frequencies showed that for the 
total sample, 64.6 % (n= 102) of participants had been treated with hormone therapy, which 
included single or combination medications such as anastrazole, letrozole, levothyroxine, 
tamoxifen, Herceptin, or other hormone medications. There was no statistically significant 
difference (p = .233) between MBSR(BC) or UC groups for hormone therapy. At the baseline 
time point of this study, it had been less than one year for most (n=121, or 76.6%) participants 
since the end of cancer treatment. There was a statistically significant difference (p=.041) 
between the MBSR(BC) and UC groups for time since treatment. Between groups, nearly twice 
as many of the MBSR(BC) group participants (n=23, or 30.7%) were more than one year since 
cancer treatment end, versus the UC group participants (n=14, or 16.9%).  
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Table 2. Clinical History Data (Stage of Disease, Surgery Type, Treatment Type, and Time Since 
Treatment) for Participants by Randomization Assignment by Frequency and Percent 
Variable 
 
Total 
N=158 
MBSR(BC) 
n=75 
Usual Care 
n=83 
p value 
Cancer Stage, n (%) 
0 
I 
II 
III 
 
Surgery Type, n (%) 
Lumpectomy 
Mastectomy 
 
Treatment Type, n (%) 
Chemotherapy 
Radiation 
Chemotherapy and Radiation 
No Chemo or Radiation 
 
Hormonal Therapy Status, n (%) 
Yes 
No 
 
Time Since Treatment, n (%) 
<1 Year 
1 to 2 Years 
 
 
18 (11.4%) 
61 (38.6%) 
54 (34.2%) 
25 (15.8%) 
 
 
65 (41.1%) 
93 (58.9%) 
 
 
22 (13.9%) 
41 (25.9%) 
48 (30.4%) 
47 (29.7%) 
 
 
102 (64.6%) 
56 (35.4%) 
 
 
121 (76.6%) 
37 (23.4%) 
 
7 (9.3%) 
28 (37.3%) 
29 (38.7%) 
11 (14.7%) 
 
 
33 (44%) 
42 (56%) 
 
 
9 (12%) 
19 (25.3%) 
24 (32%) 
23 (30.7%) 
 
 
23 (30.7%) 
52 (69.3%) 
 
 
52 (69.3%) 
23 (30.7%) 
 
11 (13.3%) 
33 (39.8%) 
25 (30.1%) 
14 (16.9%) 
 
 
32 (38.5%) 
51 (61.5%) 
 
 
13 (15.7%) 
22 (26.5%) 
24 (28.9%) 
24 (28.9%) 
 
 
33 (39.8%) 
50 (60.2%) 
 
 
69 (83.1%) 
14 (16.9%) 
.670 
 
 
 
 
 
.487 
 
 
 
.905 
 
 
 
 
 
.233 
 
 
 
.041 
 
The demographic characteristics within this study’s subset (N = 158) were similar to 
those found within the parent study. The average age among BCS in this study was 58.4 years, 
versus 56.5 years among the 322 BCS in the parent study (Lengacher et al., 2016). Among BCS 
in the parent study, 69.4% of participants were white, non-Hispanic, which is lower than in this 
study’s sample (89%). This is due to the exclusion of other races and ethnicities, as the sample 
size would not allow for genetic analyses among those groups. Most BCS were married in both 
the parent study (64.4%) and this study (70.9%). Most BCS were college educated in both the 
parent study (some college or above = 82.2%) and this study (some college or above = 75.3%), 
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and two-thirds were not working in both studies. A majority of BCS had an annual household 
income of $40,000 to less than $80,000 in both the parent study (24.2%) and this study (29.1%).  
The clinical characteristics within this study’s subset (N = 158) were also similar to those 
found within the parent study. However, more patients were diagnosed with Stage II cancer in 
the parent study (35.7%), whereas more patients were diagnosed with Stage I cancer in this 
study’s subsample (38.6%). A majority of patients in both studies received mastectomy (parent 
study, 53.4%; this study, 58.9%) versus lumpectomy and a combination of chemotherapy and 
radiation (parent study, 35.7%; this study, 30.4%) versus other types of treatments. Finally, the 
majority of patients were also on hormone treatment in both the parent study (55.9%) and this 
study’s subsample (64.6%) as well.  
In summary, randomization successfully controlled for most potential differences 
between groups (MBSR(BC) and UC) in demographic and clinical history data characteristics. 
However, the MBSR(BC) and UC groups were significantly different for time since treatment, 
with more time since treatment (at least one year) for the MBSR(BC) group than the UC group. 
Demographic and clinical characteristics were similar among BCS within the parent study and 
this study’s subset. 
Characteristics in Candidate SNPs 
 Prior to analysis of the associations of the SNPs (rs4680, rs16944, rs1800795) with pain 
and fatigue outcomes, characteristics of the SNPs were identified and presented in Table 3. The 
wild-type alleles for this sample were determined to be (A) for COMT SNP rs4680, (G) for IL1B 
SNP rs16944, and (G) for IL6 SNP rs1800795. The minor allele frequency (MAF) for each SNP 
was determined to be 0.46 for SNP rs4680, 0.32 for rs16944, and 0.38 for rs1800795. The 
genotype distributions for the SNPs in this study were tested for and passed Hardy-Weinberg 
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equilibrium, with no statistically significant differences (p’s > .05). Hardy-Weinberg equilibrium 
suggests that if the general population have allele frequencies of a and b, the sample should have 
allele frequencies of a2, 2ab, and b2. This method was used to reduce the likelihood of false 
results from genotyping error.  
  
		 51	
Table 3. Characteristics of Candidate SNPs 
     Poly/HT/WT   
Gene 
Symbol 
SNP ID Chr/Or Allele 
(P/W) 
MAF MBSR(BC) 
(n = 75) 
UC 
(n = 83) 
HWE Function 
COMT rs4680 22/For G/A 0.46 13/38/24 21/38/24 0.96 Missense Val158Met affects 
dopamine levels in the brain (Stein et 
al., 2006) 
IL1B rs16944 2/For A/G 0.32 10/38/27 4/35/44 0.85 Affects plasma levels of IL1B 
IL6 rs1800795 7/For C/G 0.38 11/36/28 10/41/32 0.94 Affects plasma levels of IL6 
 
 
Note. SNP = single nucleotide polymorphism; Chr = chromosome; Or = orientation; COMT = catechol-O-methyltransferase; IL1B = 
interleukin 1, beta; IL6 = interleukin 6; Allele (P/W) = polymorphic/wild; MAF = minor allele frequency; Poly/HT/WT = homozygous 
polymorphic/heterozygous polymorphic/wild; For = forward.  
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Results Aim 1 
 The first aim of this study was to identify specific genotypes related to symptoms of 
fatigue and pain. The hypothesis for this aim was that specific genotypes are associated with 
higher or lower levels of pain and fatigue among BCS. To identify what specific genotypes of 
the three candidate SNPs were significantly associated with fatigue and pain symptoms at 
baseline, trend analyses using one-way linear ANOVAs were performed in SPSS among all 
participants (MBSR(BC), N = 75; and UC, N = 83), but found no statistically significant 
correlations (see Tables 4-6).  
First, for SNP rs4680 in COMT gene, neither AA, AG, nor GG genotype were associated 
with a difference in mean scores on fatigue severity, fatigue interference, pain severity, or pain 
interference (see Table 4). For fatigue severity, there was no linear relationship among mean 
scores from AA to AG to GG, with mean scores of 14.63, 14.33, and 15.59 respectively. For 
fatigue interference, there was no linear relationship in mean scores as well, with mean scores of 
27.17, 25.68, and 27.15 for AA, AG, and GG respectively. The same occurred for pain severity, 
with no linear pattern for AA, AG, and GG with mean scores of 8.88, 8.63, and 9.32 
respectively. Although genotype did follow a linear pattern for mean scores for pain interference, 
with a consistent increase in mean scores from AA to GG (AA = 13.15; AG = 14.64; GG = 
16.79), this was not statistically significant (p = .328). 
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Table 4. One-Way ANOVA Linear Trend Analysis between SNP rs4680 in gene COMT and Pain 
and Fatigue Scores  
 
Symptom Outcome 
Measure 
Genotype Mean SD F p-value 
Fatigue Severity      
 AA 14.63 8.06 .285 .594 
 AG 14.33 8.16   
 GG 15.59 7.77   
Fatigue Interference      
 AA 27.17 19.63 .000 .997 
 AG 25.68 21.77   
 GG 27.15 18.54   
 
Pain Severity 
     
 AA 8.88 8.27 .059 .808 
 AG 8.63 8.21   
 GG 9.32 8.22   
 
Pain Interference 
     
 AA 13.15 14.53 .963 .328 
 AG 14.64 17.84   
 GG 16.79 16.38   
Note. COMT = catechol-O-methyltransferase; SNP = single nucleotide polymorphism 
 
 
Second, for SNP rs1800795 in gene IL6, neither CC, CG, or GG genotypes were 
associated with a difference in mean scores on fatigue severity, fatigue interference, pain 
severity, or pain interference (see Table 5). For fatigue severity, there was no linear relationship 
among mean scores for CC, CG, and GG genotypes, with mean scores of 14.35, 14.22, and 15.42 
respectively. For fatigue interference, there was no linear relationship in mean scores as well, 
with mean scores of 24.67, 24.18, and 29.98 for CC, CG, and GG respectively. For pain severity, 
there did appear to be a linear pattern among scores for CC, CG, and GG with mean scores of 
8.81, 8.82, and 8.92 respectively, however, this was not significant (p = .959). The same 
occurred for pain interference, with a linear increase in scores from CC to CG to GG, however, 
this also was not significant (p = .506). 
		 54	
 
Table 5. One-Way ANOVA Trend Analysis Between SNP rs1800795 in gene IL6 and Pain and 
Fatigue Scores  
 
Symptom Outcome 
Measure 
Genotype Mean SD F p-value 
Fatigue Severity      
 CC 14.35 7.84 .274 .601 
 CG 14.22 8.46   
 GG 15.42 7.54   
Fatigue Interference      
 CC 24.67 19.06 1.067 .303 
 CG 24.18 20.19   
 GG 29.98 20.84   
Pain Severity      
 CC 8.81 8.17 .003 .959 
 CG 8.82 8.76   
 GG 8.92 7.54   
Pain Interference      
 CC 13.14 15.20 .445 .506 
 CG 14.05 17.26   
 GG 15.95 16.20   
Note. IL6 = interleukin 6; SNP = single nucleotide polymorphism 
 
 
 Finally, for SNP rs16944 in gene IL1B, neither AA, AG, or GG genotypes were 
associated with a difference in mean scores on fatigue severity, fatigue interference, pain 
severity, or pain interference (see Table 6). There was no linear pattern from AA to AG to GG 
for fatigue severity, with mean scores of 14.36, 13.81, and 15.66 respectively. Although there did 
appear to be a linear pattern among scores for AA, AG, and GG for fatigue interference, with 
mean scores of 24.14, 24.42, and 28.99 respectively, this was not significant (p = .417). There 
was no linear pattern for pain severity genotypes, with AA, AG, and GG scores of 10.01, 7.60, 
and 9.90 respectively. Finally, was no linear pattern for pain interference, with mean scores for 
AA, AG, and GG genotypes of 15.93, 11.97, and 17.15 respectively. 
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Table 6. One-Way ANOVA Trend Analysis Between SNP rs16944 in gene IL1B and Pain and 
Fatigue Scores  
 
Symptom Outcome 
Measure 
Genotype Mean SD F p-value 
Fatigue Severity      
 AA 14.36 7.59 .310 .578 
 AG 13.81 8.12   
 GG 15.66 7.98   
Fatigue Interference      
 AA 24.14 20.41 .662 .417 
 AG 24.42 20.04   
 GG 28.99 20.68   
 
Pain Severity 
     
 AA 10.07 7.18 .005 .943 
 AG 7.60 7.91   
 GG 9.90 8.55   
 
Pain Interference 
     
 AA 15.93 15.57 .065 .799 
 AG 11.97 15.74   
 GG 17.15 17.29   
Note. IL1B = interleukin 1 beta; SNP = single nucleotide polymorphism 
  
In summary, the results of the aim 1 one-way linear ANOVAs that explored the 
relationships between specific genotypes and fatigue or pain scores found no statistically 
significant correlations (p’s > .05) for all SNPs.  
Results Aim 2 
 
The second aim of this study was to explore whether single nucleotide polymorphism 
(SNP) rs1800795 in gene IL6, SNP rs16944 in gene IL1B, and SNP rs4680 in gene COMT, 
moderate the effects of the MBSR(BC) intervention on fatigue and/or pain symptoms. Although 
there were no linear relationships between genotypes and mean scores on FSI and BPI 
measurements from Aim 1, the possibility of genetic moderation of FSI and BPI scores from 
MBSR(BC) remained, as Aim 1 and Aim 2 were not conditional upon one another. Groups were 
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compared by assignment (MBSR(BC) versus UC) and genotype (AA, AG, GG or CC, CG, GG) 
to show the changes for mean fatigue and pain scores over 12 weeks between groups. This 
allowed the exploration of potential genetic moderators of fatigue and/or pain symptoms in BCS 
as well as moderation of fatigue and/or pain symptom outcomes resulting from the MBSR(BC) 
intervention. Three models were used (Additive, Dominant, and Recessive for the polymorphic 
alleles) and the model that fit the hypotheses best was included. To further explore genetic 
moderation of fatigue and pain outcomes resulting from MBSR(BC), Linear Mixed Model 
(LMM) analyses were performed. Again, three models (Additive, Dominant, and Recessive) 
were used and the model that fit the hypotheses best was included.  
COMT. For COMT SNP rs4680, when comparing mean scores between groups by 
assignment (MBSR(BC) versus UC) and genotype (AA, AG, GG) during the active time of the 
intervention (baseline to six weeks) through 12-week follow-up, it appeared that genotype may 
have had an impact on fatigue severity scores (see Figure 3). In Figure 3, MBSR(BC) 
participants with GG genotype scored higher for fatigue severity than other participants within 
other groups at baseline. MBSR(BC) may have had a positive effect on fatigue severity for those 
with GG genotype, as fatigue severity scores were higher at baseline and decreased more than 
those with other genotypes (AA or AG) from baseline and 12 weeks. However, in this study, the 
sample size was small and because the minor allele for SNP rs4680 was (G) and there were only 
13 participants in the MBSR(BC) group with GG genotype (see table 3), this may have affected 
the results as the higher baseline mean score among that group may have influenced the 
regression to the mean. 
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Figure 3. Fatigue Severity Scores from Baseline to 6 and 12 Weeks for COMT. A comparison of 
means was used to compare improvement in fatigue severity scores between groups and explore 
potential genetic moderation of outcomes. MBSR = mindfulness-based stress reduction for breast 
cancer survivor group; UC = usual care group; UC AA = usual care group with AA genotype; 
UC AG = usual care group with AG genotype; UC GG = usual care group with GG genotype; 
MBSR AA = MBSR group with AA genotype; MBSR AG = MBSR group with AG genotype; 
MBSR GG = MBSR group with GG genotype 
 
To further explore the possibility that genotype moderated fatigue severity symptoms and 
the effects of MBSR(BC), linear mixed models (LMM) were used to assess interactions between 
time (baseline to 6 and 12 weeks), assignment (MBSR(BC) versus UC), and genotype (AA, AG, 
or GG), which resulted in no significant findings. 
 Table 7 illustrates that the results of LMM show that fatigue severity scores seemed to 
improve over time, regardless of assignment to MBSR(BC) or UC, which approached 
significance F (2, 156) = 2.458, p = .089. However, there were no significant interactions 
between time and genotype, time and assignment, or genotype and assignment at p’s > .05.  
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Table 7. Linear Mixed Model Results for Fatigue Severity by Genotype, Assignment, and Time 
for COMT rs4680  
Source df (num, den) F value p value 
Time 
Assignment 
(2, 156) 
(1, 156) 
2.458 
.557 
.089 
.457 
COMT Additive (1, 156) .391 .677 
Time*COMT Additive 
Time*Assignment 
COMT Additive*Assignment 
(4, 156) 
(2, 156) 
(2, 154) 
 
1.070 
1.383 
1.667 
.374 
.254 
.192 
Note. COMT = Catechol-O-methyltransferase gene; df = degrees of freedom; num = numerator; 
den = denominator 
 
 
There were also no significant findings for genetic moderation of fatigue interference for 
COMT SNP rs4680.  Figure 4 illustrates that genotype did not have an effect on scores in the 
MBSR(BC) group, as participants with either AA, AG, or GG genotype all similarly benefited 
from the intervention. However, among those with GG genotype, those in the MBSR(BC) group 
had a decrease in fatigue interference scores from baseline to six weeks, whereas scores 
increased in the UC group. To further explore the possibility that genotype moderated fatigue 
interference and/or the effects of MBSR(BC), LMM were used and found no significant 
interactions of time, assignment, or genotype. 
 
		 59	
 
Figure 4. Fatigue Interference Scores from Baseline to 6 and 12 Weeks for COMT. A 
comparison of means was used to compare improvement in fatigue interference scores between 
groups and explore potential genetic moderation of outcomes. MBSR = mindfulness-based stress 
reduction for breast cancer survivor group; UC = usual care group; UC AA = usual care group 
with AA genotype; UC AG = usual care group with AG genotype; UC GG = usual care group 
with GG genotype; MBSR AA = MBSR group with AA genotype; MBSR AG = MBSR group 
with AG genotype; MBSR GG = MBSR group with GG genotype 
 
Table 8 illustrates that neither time, MBSR(BC), or genotype affected fatigue 
interference scores. This means that whether time passed, if participants were in the UC or 
MBSR(BC) group, or if they had a specific genotype, these interactions did not contribute to a 
decrease in fatigue interference. 
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Table 8. Linear Mixed Model Results for Fatigue Interference by Genotype, Assignment, and 
Time for COMT rs4680  
Source df (num, den) F value p value 
Time 
Assignment 
(2, 156) 
(1, 156) 
2.088 
.528 
.127 
.469 
COMT Additive (2, 156) .297 .744 
Time*COMT Additive 
Time*Assignment 
COMT Additive*Assignment 
(4, 156) 
(2, 156) 
(2, 154) 
 
1.018 
1.211 
.371 
.400 
.301 
.690 
Note. COMT = Catechol-O-methyltransferase gene; df = degrees of freedom; num = numerator; 
den = denominator 
 
A similar result occurred for pain severity scores for COMT SNP rs4680, with no 
significant findings, Although Figure 5 illustrates that participants with GG genotype may have 
benefited more from the MBSR(BC) intervention between baseline and six weeks than those 
with AA or AG genotype, LMM were implemented and found no significant interaction.  
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Figure 5. Pain Severity Scores from Baseline to 6 and 12 Weeks for COMT. A comparison of 
means was used to compare improvement in pain severity scores between groups and explore 
potential genetic moderation of outcomes. MBSR = mindfulness-based stress reduction for breast 
cancer survivor group; UC = usual care group; UC AA = usual care group with AA genotype; 
UC AG = usual care group with AG genotype; UC GG = usual care group with GG genotype; 
MBSR AA = MBSR group with AA genotype; MBSR AG = MBSR group with AG genotype; 
MBSR GG = MBSR group with GG genotype 
 
Table 9 illustrates the results of LMM, which show that pain severity scores may have 
improved over time, regardless of assignment to MBSR(BC) or UC, as the main effect of time 
approached significance F (2, 156) = 2.548, p = .081. However, there were no significant 
interactions for the main effects of assignment or genotype, nor interactions between time and 
genotype, time and assignment, or genotype and assignment. 
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Table 9. Linear Mixed Model Results for Pain Severity by Genotype, Assignment, and Time for 
COMT rs4680  
Source df (num, den) F value p value 
Time 
Assignment 
(2, 156) 
(1, 156) 
2.548 
.364 
.081 
.547 
COMT Additive (2, 156) .087 .917 
Time*COMT Additive 
Time*Assignment 
COMT Additive*Assignment 
(4, 156) 
(2, 156) 
(2, 154) 
 
.710 
.196 
1.939 
.586 
.822 
.147 
Note. COMT = Catechol-O-methyltransferase gene; df = degrees of freedom; num = numerator; 
den = denominator 
 
 
When comparing mean scores from baseline to six and 12 weeks for pain interference for 
COMT SNP rs4680, it did not appear that genotype had an effect on scores or moderated the 
effects of MBSR(BC), as shown in Figure 6. MBSR(BC) participants with either AA, AG, or 
GG genotype similarly benefited during the intervention (baseline to six weeks). 
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Figure 6. Pain Interference Scores from Baseline to 6 and 12 Weeks for COMT. A comparison of 
means was used to compare improvement in pain severity scores between groups and explore 
potential genetic moderation of outcomes. MBSR = mindfulness-based stress reduction for breast 
cancer survivor group; UC = usual care group; UC AA = usual care group with AA genotype; 
UC AG = usual care group with AG genotype; UC GG = usual care group with GG genotype; 
MBSR AA = MBSR group with AA genotype; MBSR AG = MBSR group with AG genotype; 
MBSR GG = MBSR group with GG genotype 
 
Table 10 illustrates the results of LMM, which further explored the possibility that 
genotype moderated pain interference and the effects of MBSR(BC). Results suggest no 
significant interactions for the main effects of time, assignment, or genotype, or the interactions 
between time and genotype, time and assignment, and genotype by assignment. 
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Table 10. Linear Mixed Model Results for Pain Interference by Genotype, Assignment, and Time 
for COMT rs4680 (Additive Model) 
Source df (num, den) F value p value 
Time 
Assignment 
(2, 156) 
(1, 156) 
2.122 
.153 
.123 
.696 
COMT Additive (2, 156) .266 .767 
Time*COMT Additive 
Time*Assignment 
COMT Additive*Assignment 
(4, 156) 
(2, 156) 
(2, 154) 
 
.935 
.460 
.526 
.445 
.632 
.592 
Note. COMT = Catechol-O-methyltransferase gene; df = degrees of freedom; num = numerator; 
den = denominator 
 
 
IL1B. For IL1B SNP rs16944, when comparing mean scores from baseline to six and 12 
weeks for fatigue severity, it did not appear that genotype had an effect on scores or moderated 
the effects of MBSR(BC) (see Figure 7). MBSR(BC) participants with either AA, AG, or GG 
genotype similarly benefited from the intervention between baseline and six weeks. 
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Figure 7. Fatigue Severity Scores from Baseline to 6 and 12 Weeks for IL1B. A comparison of 
means was used to compare improvement in fatigue severity scores between groups and explore 
potential genetic moderation of outcomes. MBSR = mindfulness-based stress reduction for breast 
cancer survivor group; UC = usual care group; UC AA = usual care group with AA genotype; 
UC AG = usual care group with AG genotype; UC GG = usual care group with GG genotype; 
MBSR AA = MBSR group with AA genotype; MBSR AG = MBSR group with AG genotype; 
MBSR GG = MBSR group with GG genotype 
 
Table 11 illustrates the results of LMM, which further explored the possibility that 
genotype moderated fatigue severity and/or the effects of MBSR(BC). Results show that fatigue 
severity scores may have improved over time, regardless of assignment to MBSR(BC) or UC, as 
the main effect of time approached significance F (2, 156) = 2.670, p = .072. However, there 
were no significant interactions for the main effects of assignment or genotype, nor interactions 
between time and genotype, time and assignment, or genotype and assignment. 
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Table 11. Linear Mixed Model Results for Fatigue Severity by Genotype, Assignment, and Time 
for IL1B rs16944  
Source df (num, den) F value p value 
Time 
Assignment 
(2, 156) 
(1, 156) 
2.670 
.642 
.072 
.424 
IL1B Additive (2, 156) .035 .966 
Time*IL1B Additive 
Time*Assignment 
IL1B Additive*Assignment 
(4, 156) 
(2, 156) 
(2, 154) 
 
.691 
1.287 
.369 
.599 
.279 
.692 
Note. IL1B = Interleukin 1 beta gene; df = degrees of freedom; num = numerator; den = 
denominator 
 
 
When comparing mean scores from baseline to six and 12 weeks for fatigue interference 
for IL1B SNP rs16944, it did appear that genotype may have moderated the effects of 
MBSR(BC) (see Figure 8). Among those with AA genotype, those in the MBSR(BC) group had 
a decrease in fatigue interference scores from baseline to six and 12 weeks, whereas scores 
increased in the UC group. However, in this study, the sample size was small and because the 
minor allele for SNP rs16944 was (A), this may have affected the results. 
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Figure 8. Fatigue Interference Scores from Baseline to 6 and 12 Weeks for IL1B. A comparison 
of means was used to compare improvement in fatigue interference scores between groups and 
explore potential genetic moderation of outcomes. MBSR = Mindfulness-based stress reduction 
for breast cancer survivor group; UC = Usual care group; UC AA = usual care group with AA 
genotype; UC AG = usual care group with AG genotype; UC GG = usual care group with GG 
genotype; MBSR AA = MBSR group with AA genotype; MBSR AG = MBSR group with AG 
genotype; MBSR GG = MBSR group with GG genotype 
 
To further explore the possibility that genotype moderated the effects of MBSR(BC) on 
fatigue interference, LMM were implemented. Table 12 illustrates a decrease in fatigue 
interference scores over time among both MBSR(BC) and UC groups, which approached 
significance F (2, 156) =2.531, p = .083. This means that fatigue interference may have 
improved over time, regardless of assignment or genotype. However, there were no significant 
interactions for the main effect of assignment or genotype, nor for the interactions between time 
and assignment, time and genotype, or genotype and assignment. 
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Table 12. Linear Mixed Model Results for Fatigue Interference by Genotype, Assignment, and 
Time for IL1B rs16944  
Source df (num, den) F value p value 
Time 
Assignment 
(2, 156) 
(1, 163) 
2.531 
.604 
.083 
.438 
IL1B Additive (2, 156) .041 .960 
Time*IL1B Additive 
Time*Assignment 
IL1B Additive*Assignment 
(4, 156) 
(2, 156) 
(2, 154) 
 
.653 
1.104 
.484 
.625 
.334 
.617 
Note. IL1B = Interleukin 1 beta gene; df = degrees of freedom; num = numerator; den = 
denominator 
 
When comparing mean scores from baseline to six and 12 weeks for IL1B SNP rs16944, 
it appeared that genotype possibly moderated pain severity in the MBSR(BC) group, as those 
with AG genotype seemed to benefit less from the intervention (baseline to six weeks) than those 
with AA or AG genotype (see Figure 9).  
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Figure 9. Pain Severity Scores from Baseline to 6 and 12 Weeks for IL1B. A comparison of 
means was used to compare improvement in pain severity scores between groups and explore 
potential genetic moderation of outcomes. MBSR = Mindfulness-based stress reduction for 
breast cancer survivor group; UC = Usual care group; UC AA = usual care group with AA 
genotype; UC AG = usual care group with AG genotype; UC GG = usual care group with GG 
genotype; MBSR AA = MBSR group with AA genotype; MBSR AG = MBSR group with AG 
genotype; MBSR GG = MBSR group with GG genotype 
 
To further explore the possibility that genotype moderated pain severity and/or the effects 
of MBSR(BC), LMM were implemented. Table 13 illustrates that LMM resulted in no 
significant findings for the main effects of time, assignment, or genotype, nor for interactions 
between time and genotype, time and assignment, or genotype and assignment.  
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Table 13. Linear Mixed Model Results for Pain Severity by Genotype, Assignment, and Time for 
IL1B rs16944  
Source df (num, den) F value p value 
Time 
Assignment 
(2, 156) 
(1, 158) 
.638 
.730 
.530 
.394 
IL1B Additive (2, 156) .623 .538 
Time*IL1B Additive 
Time*Assignment 
IL1B Additive*Assignment 
(4, 156) 
(2, 156) 
(2, 154) 
 
.301 
.381 
.110 
.877 
.684 
.896 
Note. IL1B = Interleukin 1 beta gene; df = degrees of freedom; num = numerator; den = 
denominator 
 
When comparing mean scores from baseline to six and 12 weeks for IL1B SNP rs16944, 
it did not appear that genotype moderated pain interference or the effects of MBSR(BC) (see 
Figure 10). However, Figure 10 illustrates the lasting effects of MBSR(BC), as intervention 
participants experienced a decrease in pain interference even after the end of six weeks, which 
continued until 12-week follow up. 
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Figure 10. Pain Interference Scores from Baseline to 6 and 12 Weeks for IL1B. A comparison of 
means was used to compare improvement in pain interference scores between groups and 
explore potential genetic moderation of outcomes. MBSR = Mindfulness-based stress reduction 
for breast cancer survivor group; UC = Usual care group; UC AA = usual care group with AA 
genotype; UC AG = usual care group with AG genotype; UC GG = usual care group with GG 
genotype; MBSR AA = MBSR group with AA genotype; MBSR AG = MBSR group with AG 
genotype; MBSR GG = MBSR group with GG genotype 
 
Lastly, to further explore the possibility that genotype moderated pain interference and/or 
the effects of MBSR(BC), LMM were used but found no significant results. However, table 14 
illustrates a decrease in pain interference scores over time among both MBSR(BC) and UC 
groups, which approached significance F (2, 156) =2.959, p = .055. This means that pain 
interference may have improved over time, regardless of assignment or genotype. However, 
there were no significant results for the main effects of assignment or genotype, nor for the 
interactions between time and genotype, time and assignment, or genotype and assignment. 
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Table 14. Linear Mixed Model Results for Pain Interference by Genotype, Assignment, and Time 
for IL1B rs16944  
Source df (num, den) F value p value 
Time 
Assignment 
(2, 156) 
(1, 161) 
2.959 
.279 
.055 
.598 
IL1B Additive (2, 156) .137 .872 
Time*IL1B Additive 
Time*Assignment 
IL1B Additive*Assignment 
(4, 156) 
(2, 156) 
(2, 154) 
 
1.658 
.449 
.143 
.163 
.639 
.867 
Note. IL1B = Interleukin 1 beta gene; df = degrees of freedom; num = numerator; den = 
denominator 
 
IL6. For IL6 SNP rs1800795, when comparing mean scores from baseline to six and 12 
weeks for fatigue severity for IL6 SNP rs1800795, it did appear that genotype and assignment 
had a moderating effect on fatigue severity (see Figure 11). Among those with CG genotype, 
participants in the MBSR(BC) group experienced a decrease in fatigue severity scores during the 
active time of the intervention (baseline to six weeks). 
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Figure 11. Fatigue Severity Scores from Baseline to 6 and 12 Weeks for IL6. A comparison of 
means was used to compare improvement in fatigue severity scores between groups and explore 
potential genetic moderation of outcomes. MBSR = Mindfulness-based stress reduction for 
breast cancer survivor group; UC = Usual care group; UC CC = usual care group with CC 
genotype; UC CG = usual care group with CG genotype; UC GG = usual care group with GG 
genotype; MBSR CC = MBSR group with CC genotype; MBSR CG = MBSR group with CG 
genotype; MBSR GG = MBSR group with GG genotype 
 
To further explore the possibility that assignment and genotype moderated the outcome 
of fatigue severity, LMM were used and found a significant interaction F (2, 154) = 5.172, p = 
.007 (see table 15). This suggests that being in the MBSR(BC) group and having a specific 
genotype affected fatigue severity scores. 
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Table 15. Linear Mixed Model Results for Fatigue Severity by Genotype, Assignment, and Time 
for IL6 rs1800795  
Source df (num, den) F value p value 
Time 
Assignment 
(2, 156) 
(1, 156) 
1.305 
.714 
.274 
.399 
IL6 Additive (2, 156) 1.944 .147 
Time*IL6 Additive 
Time*Assignment 
IL6 Additive*Assignment 
(4, 156) 
(2, 156) 
(2, 154) 
 
1.065 
1.727 
5.172 
.376 
.181 
.007* 
Note. IL6 = Interleukin 6 gene; df = degrees of freedom; num = numerator; den = denominator; 
*p<.05 
 
 Table 16 reports mean scores and standard deviations for fatigue severity at baseline and 
12 weeks for IL6 by assignment and genotype, which further supports the results displayed in 
Figure 11. It may be interpreted that MBSR participants with CG genotype experienced the 
largest drop in fatigue severity scores from 17.08 at baseline to 10.97 at 12 weeks, with a 
medium to large effect size of d = 0.72.  
Table 16. Mean Scores and Standard Deviations for Fatigue Severity at Baseline and 12 Weeks 
for IL6 rs1800795 by Assignment and Genotype 
Group Baseline 12 Weeks 
Assignment and Genotype Mean Standard 
Deviation 
Mean Standard 
Deviation 
UC CC  13.40 8.396 10.27 7.754 
UC CG 11.71 7.191 11.42 8.397 
UC GG 16.94 8.207 15.35 9.120 
MBSR CC 15.21 7.591 12.91 8.093 
MBSR CG 17.08 8.977 10.97 7.829 
MBSR GG 13.68 6.412 12.18 6.532 
 
There was a similar finding when comparing mean scores from baseline to six and 12 
weeks for fatigue interference for IL6 SNP rs1800795. Figure 12 illustrates that it did appear that 
genotype had a moderating effect on the decrease in scores resulting from MBSR(BC). Overall, 
participants in the MBSR(BC) group seemed to experience a greater decrease in mean scores for 
fatigue interference if they had CG genotype versus CC or GG genotypes.  
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Figure 12. Fatigue Interference Scores from Baseline to 6 and 12 Weeks for IL6. A comparison 
of means was used to compare improvement in fatigue interference scores between groups and 
explore potential genetic moderation of outcomes. MBSR = Mindfulness-based stress reduction 
for breast cancer survivor group; UC = Usual care groupUC CC = usual care group with CC 
genotype; UC CG = usual care group with CG genotype; UC GG = usual care group with GG 
genotype; MBSR CC = MBSR group with CC genotype; MBSR CG = MBSR group with CG 
genotype; MBSR GG = MBSR group with GG genotype 
 
To further explore this possibility, LMM were implemented and found a significant 
interaction F (2, 154) = 3.548, p = .031 between genotype and assignment (see table 16). This 
suggests that being in the MBSR(BC) group and having a specific genotype affected fatigue 
interference scores. 
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Table 17. Linear Mixed Model Results for Fatigue Interference by Genotype, Assignment, and 
Time for IL6 rs1800795  
Source df (num, den) F value p value 
Time 
Assignment 
(2, 156) 
(1, 158) 
1.066 
.600 
.347 
.440 
IL6 Additive (2, 155) 1.817 .166 
Time*IL6 Additive 
Time*Assignment 
IL6 Additive*Assignment 
(4, 156) 
(2, 156) 
(2, 154) 
 
1.143 
1.538 
3.548 
.339 
.218 
.031* 
Note. IL6 = Interleukin 6 gene; df = degrees of freedom; num = numerator; den = denominator; 
*p<.05 
 
Table 18 reports mean scores and standard deviations for fatigue interference at baseline 
and 12 weeks for IL6 by assignment and genotype, which further supports the results displayed 
in Figure 12. It may be interpreted that MBSR participants with CG genotype experienced the 
largest drop in fatigue interference scores from 30.31 at baseline to 20.29 at 12 weeks, with a 
small to medium effect size of d = 0.48. 
Table 18. Mean Scores and Standard Deviations for Fatigue Interference at Baseline and 12 
Weeks for IL6 rs1800795 by Assignment and Genotype 
Group Baseline 12 Weeks 
Assignment and Genotype Mean Standard 
Deviation 
Mean Standard 
Deviation 
UC CC  25.10 20.212 17.20 14.242 
UC CG 18.80 16.629 18.45 18.970 
UC GG 33.34 21.977 28.74 21.288 
MBSR CC 24.27 18.932 24.09 23.704 
MBSR CG 30.31 22.280 20.29 19.170 
MBSR GG 26.14 19.125 18.18 12.681 
 
When comparing mean scores from baseline to six and 12 weeks for pain severity for IL6 
SNP rs1800795, it did appear that genotype had a moderating effect on the decrease in scores 
resulting from MBSR(BC) (see Figure 13). Participants with CG genotype appeared to benefit 
more from MBSR(BC) from baseline to six weeks than those with CC or GG genotypes. From 
baseline to six weeks, pain severity scores actually increased in MBSR(BC) participants with CC 
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genotype, and at 12 weeks, pain severity scores returned to baseline levels, showing no benefit of 
MBSR(BC). Similarly, MBSR(BC) participants with GG genotype experienced an increase in 
pain severity scores from baseline to six weeks, showing no benefit during the intervention 
period. 
 
Figure 13. Pain Severity Scores from Baseline to 6 and 12 Weeks for IL6. A comparison of 
means was used to compare improvement in pain severity scores between groups and explore 
potential genetic moderation of outcomes. MBSR = Mindfulness-based stress reduction for 
breast cancer survivor group; UC = Usual care groupUC CC = usual care group with CC 
genotype; UC CG = usual care group with CG genotype; UC GG = usual care group with GG 
genotype; MBSR CC = MBSR group with CC genotype; MBSR CG = MBSR group with CG 
genotype; MBSR GG = MBSR group with GG genotype 
 
To further explore the possibility that genotype moderated the outcome of pain severity 
within the MBSR(BC) group, LMM were used and confirmed a significant interaction between 
genotype and assignment F (2, 154) = 4.294, p = .015 (see table 17).   
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Table 19. Linear Mixed Model Results for Pain Severity by Genotype, Assignment, and Time for 
IL6 rs1800795 (Additive Model) 
Source df (num, den) F value p value 
Time 
Assignment 
(2, 156) 
(1, 156) 
.974 
.430 
.380 
.513 
IL6 Additive (2, 155) .722 .488 
Time*IL6 Additive 
Time*Assignment 
IL6 Additive*Assignment 
(4, 156) 
(2, 156) 
(2, 154) 
 
.658 
.250 
4.294 
.622 
.779 
.015* 
Note. IL6 = Interleukin 6 gene; df = degrees of freedom; num = numerator; den = denominator; 
*p<.05 
 
Table 20 reports mean scores and standard deviations for pain severity at baseline and 12 
weeks for IL6 by assignment and genotype, which further supports the results displayed in 
Figure 13. It may be interpreted that MBSR participants with CG genotype experienced the 
largest drop in pain severity scores from 10.86 at baseline to 7.38 at 12 weeks, with a small to 
medium effect size of d = 0.41. 
Table 20. Mean Scores and Standard Deviations for Pain Severity at Baseline and 12 Weeks for 
IL6 rs1800795 by Assignment and Genotype 
Group Baseline 12 Weeks 
Assignment and Genotype Mean Standard 
Deviation 
Mean Standard 
Deviation 
UC CC  9.60 9.97 5.70 7.24 
UC CG 7.02 7.65 5.93 6.37 
UC GG 10.72 7.50 10.02 7.79 
MBSR CC 8.09 6.55 7.91 9.04 
MBSR CG 10.86 9.57 7.38 7.39 
MBSR GG 6.86 7.17 4.71 7.29 
 
Finally, for pain interference, a comparison of mean scores from baseline to six and 12 
weeks for IL6 SNP rs1800795 suggested that genotype had a moderating effect on pain 
interference scores resulting from MBSR(BC) (see Figure 14).  
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Figure 14. Pain Interference Scores from Baseline to 6 and 12 Weeks for IL6. A comparison of 
means was used to compare improvement in pain interference scores between groups and 
explore potential genetic moderation of outcomes. MBSR = Mindfulness-based stress reduction 
for breast cancer survivor group; UC = Usual care group; UC CC = usual care group with CC 
genotype; UC CG = usual care group with CG genotype; UC GG = usual care group with GG 
genotype; MBSR CC = MBSR group with CC genotype; MBSR CG = MBSR group with CG 
genotype; MBSR GG = MBSR group with GG genotype 
 
To further explore the possibility that genotype moderated the outcome of pain 
interference within the MBSR(BC) group, LMM were implemented and confirmed a significant 
interaction between genotype and assignment F (2, 154) = 3.577, p = .030 (see table 18).  This 
means that among MBSR(BC) participants, having a specific genotype affected pain interference 
scores. 
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Table 21. Linear Mixed Model Results for Pain Interference by Genotype, Assignment, and Time 
for IL6 rs1800795  
Source df (num, den) F value p value 
Time 
Assignment 
(2, 156) 
(1, 157) 
1.147 
.221 
.320 
.639 
IL6 Additive (2, 155) 1.508 .224 
Time*IL6 Additive 
Time*Assignment 
IL6 Additive*Assignment 
(4, 156) 
(2, 156) 
(2, 154) 
 
.761 
.660 
3.577 
.552 
.518 
.030* 
Note. IL6 = Interleukin 6 gene; df = degrees of freedom; num = numerator; den = denominator; 
*p<.05 
 
Table 22 reports mean scores and standard deviations for pain interference at baseline 
and 12 weeks for IL6 by assignment and genotype, which further supports the results displayed 
in Figure 14. It may be interpreted that MBSR participants with CG genotype experienced the 
largest drop in pain interference scores from 18.19 at baseline to 11.95 at 12 weeks, with a small 
to medium effect size of d = 0.38.    
Table 22. Mean Scores and Standard Deviations for Pain Interference at Baseline and 12 Weeks 
for IL6 rs1800795 by Assignment and Genotype 
Group Baseline 12 Weeks 
Assignment and Genotype Mean Standard 
Deviation 
Mean Standard 
Deviation 
UC CC  14.20 18.16 16.00 24.55 
UC CG 10.41 14.72 8.08 11.61 
UC GG 19.66 16.95 21.84 26.46 
MBSR CC 12.18 12.77 7.95 12.40 
MBSR CG 18.19 19.13 11.95 13.81 
MBSR GG 19.66 16.95 21.84 26.46 
 
In summary, there were no significant findings for SNP rs4680 in COMT or SNP rs16944 
in IL1B. However, the results from LMM analyses suggest that time may have been in a factor in 
the improvement of fatigue severity and pain severity when assessing COMT and for fatigue 
severity, fatigue interference, and pain severity when assessing IL1B. Several significant findings 
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resulted from LMM when assessing IL6. First, LMM resulted in a significant interaction between 
genotype and assignment. Second, a comparison of means suggests that participants in the 
MBSR(BC) group who had CG genotype benefited more from the intervention than those with 
CC or GG genotypes for fatigue severity, fatigue interference, pain severity, and pain 
interference, with small to large effect sizes ranging from d = 0.38 to d = 0.72.
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Chapter Five 
Summary, Discussion, Conclusions, Implications, and Recommendations for Future Study 
Introduction 
 The final chapter of the dissertation includes a summary of the study and a discussion of 
the results, conclusions including limitations, implications for nursing, and future research 
recommendations. The purpose of this study was to identify specific genotypes involved in 
fatigue and pain symptoms and explore whether SNP rs16944 in gene IL1B, SNP rs4680 in gene 
COMT, and SNP rs1800795 in gene IL6 moderate fatigue and/or pain outcomes in BCS and 
whether the effects of the MBSR(BC) intervention on fatigue and/or pain are moderated by these 
SNPs. This genetic study and secondary data analysis conducted within the R01 MBSR Symptom 
Cluster Trial for Breast Cancer Survivors, 1R01CA131080. 
Discussion and Conclusions 
This study yielded several important findings. First, in this study of 158 BCS, most 
participants were married, college-educated (75.3%), with an average age of 58.4 years, and had 
an average annual household income of $40,000-$80,000, which were similar to the 
demographic characteristics within the parent R01 study (N = 322). The subsample of this study 
(N = 158) were not racially diverse as the sample size was too small to compare genetic 
associations across different racial groups and was therefore limited to non-Hispanic and 
Hispanic whites. In terms of clinical characteristics, most BCS were diagnosed with Stage I-II 
BC (72.8%), received mastectomy (58.9%), and received a combination of chemotherapy and 
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radiation (30.4%), and received hormone treatment (64.6%), which were similar to clinical 
characteristics in the parent study. Among the 158 participants in this study, there were no 
significant differences in age, stage of cancer, or type of cancer treatment, between MBSR(BC) 
(n = 75) and UC (n = 83) groups in this study. However, there were significantly more (p = .04) 
participants in the UC group (83.1%) within one year from end of cancer treatment compared to 
the MBSR(BC) group (69.3%), which may help explain why UC participants also experienced 
an improvement in fatigue and pain symptoms during the study, as they were closer to treatment 
end and may have been focused on trying to overcome adverse symptoms to continue with daily 
activities. 
A second finding of this study was that there were no significant correlations between 
SNPs COMT rs4680, IL1B rs16944, and IL6 rs1800975, and fatigue and pain symptoms at 
baseline. The results from one-way linear ANOVAs, which were implemented to identify 
specific genotypes associated with fatigue and pain symptoms from Aim 1, found no linear 
relationships between genotypes and mean scores on FSI and BPI measurements. Previous 
research has found associations between pain and SNPs in COMT rs4680, IL1B rs16944, and IL6 
rs1800795. For SNP COMT rs4680, the results from previous research have been mixed for 
associations between +/- pain severity and (A) and (G) alleles, with two studies (Knisely et al., 
2018; Tammimaki & Mannisto, 2012) reporting positive associations between (A) alleles and 
increased pain, and another study (Rut et al., 2014) reporting a positive association between (G) 
alleles and increased pain. The COMT enzyme is responsible for metabolizing catechol 
neurotransmitters (dopamine, adrenaline, and noradrenaline) in the brain’s prefrontal cortex. The 
(G) allele codes for valine amino acid, which results in more COMT enzyme available to 
metabolize catechol neurotransmitters and thus less extracellular dopamine, which may result in 
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a higher pain threshold and resilience to stress (Stein, Newman, Savitz, & Ramesar, 2006). 
Considering the previous research results between genotypes for SNP COMT rs4680 and pain 
have been mixed, and there were no significant associations found in this study, more research is 
needed in this area to confirm the genetic effects on the pain symptom experience. Second, for 
SNP IL1B rs16944, the results from previous research on the associations between genotype and 
fatigue have also been mixed. A study by Kober et al., 2016 reported an association between CG 
or GG genotype and higher levels of fatigue, a study by Jim et al., 2012 found no association, 
and a study by Collado-Hidalgo et al., 2008 reported an association between CC genotype and 
higher levels of fatigue. The IL1B gene provides instructions for producing pro-inflammatory 
IL1B cytokine protein, an important mediator involved in the inflammatory response, increased 
plasma levels of IL1B promote inflammation. It is unclear which genotypes promote increases in 
plasma IL1B. Considering the previous research results between genotypes for SNP IL1B 
rs16944 and fatigue have been mixed, and there were no significant associations found in this 
study, more research is needed in this area to confirm the genetic effects on the fatigue symptom 
experience. Finally, for SNP IL6 rs1800795, the results from previous research have been mixed 
for associations between +/- fatigue severity and genotype, with one study (Collado-Hidalgo et 
al., 2008) reporting an association between both GG or CC genotype and higher levels of fatigue 
versus CG genotype, two studies (Bower et al., 2013; Shi et al., 2014) reporting an association 
between GG genotype and higher levels of fatigue, and one study (Jim et al., 2012) reporting an 
association between CG genotype and higher levels of fatigue. Similar to the actions of the IL1B 
gene, the IL6 gene provides instructions for producing pro-inflammatory IL6 cytokine protein 
that is an important mediator involved in the inflammatory response and increased plasma levels 
of IL6 promote inflammation. It is unclear which genotypes promote increases in plasma IL6 and 
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considering previous research findings have been mixed for associations between SNP IL6 
rs16944 and +/- fatigue severity, more research is needed to confirm its effects on the fatigue 
symptom experience. 
A third finding of this study is that those in the MBSR(BC) group who had CG genotype 
for IL6 benefited more from the intervention than those with CC or GG genotypes for fatigue 
severity (p = .007, d = 0.72), fatigue interference (p = .031, d = 0.48), pain severity (p = .015, d = 
0.41), and pain interference (p = .030, d = 0.38. Although there were no significant findings 
identified from Aim 1, this did not mean that genotype could not moderate a change in symptom 
scores resulting from an intervention such as MBSR(BC). Therefore, a mixed model approach 
was then implemented to explore whether SNP rs1800795 in gene IL6, SNP rs16944 in 
gene IL1B, and SNP rs4680 in gene COMT, moderated the effects of the MBSR(BC) 
intervention on fatigue and/or pain symptoms from Aim 2. Linear mixed models analyzed 
genotype, assignment, and time as main effects along with the interaction of genotype x time, 
genotype x assignment (MBSR(BC) versus UC), and assignment x time. First, an interesting 
finding from Aim 2 results was that regardless of assignment, participants experienced an 
improvement in symptoms over time. This may mean that MBSR(BC) was an effective treatment 
for participants within the intervention group during the active time of the intervention, and 
control group participants may have become more attentive and concerned over their symptoms 
and found other ways to improve their symptoms. In the parent study, MBSR(BC) was 
demonstrated as an effective therapy for fatigue severity and interference (p’s < .01), with a 
small effect size for fatigue severity (d = 0.27) (Lengacher et al., 2016). Additional research has 
supported MBSR for the treatment of fatigue symptoms (Carlson & Garland, 2005) and although 
the parent study did not find benefit from MBSR for pain symptoms, another study found 
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promising results (Kvillemo & Branstrom, 2011). In this study, the significant interaction found 
between genotype and assignment suggests that MBSR(BC) participants with CG genotype for 
IL6 experience a greater improvement in fatigue severity, fatigue interference, pain severity, and 
pain interference than those with CC or GG genotypes. Among other genetic studies, the results 
have been mixed, with some studies (Collado-Hidalgo et al., 2008; Jim et al., 2012) suggesting 
that CC or CG genotype predicts more fatigue and other studies (Bower et al., 2013; Collado-
Hidalgo et al., 2008) suggesting GG genotype predicts higher levels of fatigue. There are no 
positive findings on the association between pain and SNP IL6 rs1800795 among BCS in the 
literature. However, previous research suggests that increased plasma levels of pro-inflammatory 
cytokine IL6 are associated with pain and SNP rs1800795 influences its expression rate (Kovacs 
et al., 2016). Results from this study provide preliminary evidence that SNPs in genes associated 
with inflammatory pathways moderate the effects of MBSR(BC) on improvements fatigue and 
pain symptoms in BCS and supports the hypothesis that MBSR reduces symptoms by improving 
the stress response (Kabat-Zinn, 1990; Kabat-Zinn et al., 1985, 1992). Fatigued BCS have been 
found to have increased plasma levels of IL6, IL1B, and other markers of inflammation (Bower 
et al., 2007; Collado-Hidalgo et al., 2006). Considering mind-body therapies have been found to 
reduce plasma levels of inflammatory cytokines such as IL6 (Morgan et al., 2014), a speculation 
may be made that stress-reducing programs such as MBSR(BC) help decrease inflammation in 
the body by reducing inflammatory cytokine levels and thus improve fatigue and/or pain 
symptoms.  
Exploring these associations and disseminating findings will contribute to symptom 
science and precision medicine by targeting optimal therapies for BCS based on their genetic 
profiles, which may help improve quality of life. As the symptom experience varies by 
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individual based on genetic and environmental backgrounds, medicine should not follow a “one-
size-fits-all” approach. Mind-body therapies such as MBSR(BC) are finally entering the spotlight 
in medicine research. Although this study is the first reported study to explore the genetic 
moderation of fatigue and/or pain symptoms in BCS participating in a MBSR(BC) program, it 
further supports previous research (Lengacher et al., 2015b) which found genetic moderation of 
MBSR(BC) on cognitive impairment in BCS. The major benefit of this study is to support future 
genetic research and precision medicine to help predict which treatments are more advantageous 
for patients based on their individual genes.  The major aim of the Precision Medicine Initiative 
is to expand cancer genomics to develop better treatment methods and during President Barack 
Obama’s State of the Union address, $215 million was invested towards biomedical advances to 
help supply healthcare providers with new knowledge and tools to personalize treatments for the 
best outcomes (The White House, 2015). By first discovering genetic changes and their 
associations, further research can then test targeted interventions on patients to determine the 
best outcomes. This genetic study is a step towards both identifying genetic associations with 
adverse symptoms such as pain and fatigue experienced by BCS, and exploring the genetic 
moderation of MBSR(BC) on such symptoms. 
Limitations 
There are several limitations of this study that should be mentioned. First, the sample size 
was small for a genetic study. Sufficient statistical power is critical for the detection of genetic 
association and moderation studies. Testing one SNP requires 248 cases, under the assumption of 
an odds ratio of 2, 5% prevalence, 5% minor allele frequency, 1:1 case/control ratio, and a 5% 
error rate (Hong & Park, 2012). This current study had enrolled 158 participants and tested three 
SNPs: COMT rs4680, IL1B rs16944, and IL6 rs1800795. However, this study was exploratory in 
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nature with a goal of identifying associations and moderation of effects that should be researched 
in larger future studies. A second limitation was that this study explored the presence or absence 
of SNPs and their association with symptoms experienced by BCS, however, it does not address 
gene expression. The results of this study do not bridge the gap between the presence of SNPs 
and their effects on protein synthesis. The study of gene expression can help explain the 
variability of a SNP’s effect on symptoms and increase the power of detecting their overall 
effects (Huang, VanderWeele, & Lin, 2014). Another limitation is that although specific 
genotypes were explored among genes involved in inflammatory and anti-inflammatory 
pathways, there were no direct measures of systemic levels of circulating IL6 and IL1B, which 
would have provided additional information on the underlying mechanisms for pain and fatigue 
severity. Current empirical research has primarily focused on circulating inflammatory markers, 
which has generally shown a positive association with fatigue and pain, particularly after the end 
of cancer treatment (Miaskowski & Aouizerat, 2012). In addition, since there was no assessment 
of fatigue or pain prior to a breast cancer diagnosis, so it is impossible to determine if there were 
pre-existing symptoms prior to cancer treatment. Since there was no healthy control group, 
inferences cannot be made about the relationship between these genetic variations and fatigue 
and pain in the general population or in people with other types of cancer (prostate, lung, etc.). 
Furthermore, this study included only Hispanic and non-Hispanic white women; generalizations 
to women of other races and men are limited. Finally, even though participants were randomized, 
the MBSR(BC) and UC groups were significantly (p < .05) different in terms of time since the 
end of their cancer treatment. The UC group was closer to cancer treatment end (< 1 year) than 
the MBSR(BC) group, which may have diminished the potential to determine the true influence 
of the MBSR(BC) intervention. 
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Implications for Nursing 
The nurse caring for BCS should be knowledgeable of the individual variations in fatigue 
and pain experiences, which may be influenced by genetic background. As healthcare moves 
forward into the era of precision medicine, the nurse should also be aware that because of these 
genetic differences, some patients may respond more or less to treatments aimed at improving 
adverse symptoms experienced by patients after cancer treatment. As the implementation of 
precision medicine moves forward, nurses must continue providing care while optimizing patient 
outcomes.  The nurse should also be informed of non-pharmacological treatments such as 
MBSR(BC), as discussions between the nurse and patient may occur regarding unpleasant 
symptoms resulting from cancer treatment and/or the cancer experience, and the nurse should be 
prepared to discuss what is available to the patient. Finally, educational programs should be 
further implemented to provide nurses a basic understanding of precision medicine, to help them 
understand how genetics influence subjective symptoms as well as treatment outcomes.  
Recommendations for future research. This was the first study to explore whether 
SNPs moderate the effects of a MBSR(BC) intervention on pain and/or fatigue. Although the 
exact mechanisms for fatigue and pain resulting from cancer treatment are largely unknown, 
genetic factors play a role (Doong et al., 2015; Shi et al., 2015) and genetic studies can 
contribute to the field of precision medicine, to tailor complementary and alternative medicine 
therapies to best suit patients’ needs (Grady & Gough, 2015). The future research 
recommendations, based on the findings of this current study as well as the existing scientific 
literature in this area of research, include the following: 
1. To conduct additional research exploring associations between SNPs in genes and other 
distressing symptoms experienced by BCS after treatment. 
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2. To conduct a study exploring genetic moderation of symptom outcomes resulting from 
MBSR(BC) with a larger sample size and include a healthy (non-cancer) control group. 
3. To perform a study similar to this but including other racial backgrounds. This	study	was	conducted	only	on	Hispanic	and	non-Hispanic	whites	and	the	findings	may	not	apply	to	BCS	with	more	diverse	racial	backgrounds.	Although	nucleotide	diversity	between	humans	is	about	0.1	percent,	this	study	was	limited	to	whites	only	since	the	sample	size	would	lack	precision	for	other	races,	which	were	very	few	in	the	parent	study. 
4. Combine studies of SNP analysis, gene expression, and measurement of circulating 
inflammatory and ant-inflammatory markers in a study involving BCS participating in a 
MBSR(BC) program for pain and fatigue. 
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